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ABSTRACT 
DAYNA M. HAYES: Ethanol-Induced Locomotor Sensitization and Ethanol 
Consumption: The Role of Neuropeptide Y 
(Under the direction of Todd E. Thiele) 
 
Neuropeptide Y (NPY) has been implicated in neurobiological responses to 
ethanol and in the present investigation, we aimed to further elucidate the role of 
NPY in ethanol-induced locomotor sensitization and ethanol consumption using 
genetic and advanced pharmacological manipulations. The first set of experiments 
focused on ethanol-induced locomotor behaviors. We have reported that mutant 
mice lacking normal production of the RIIβ subunit of protein kinase A (RIIβ -/- mice) 
show enhanced sensitivity to the locomotor stimulant effects of ethanol. In the 
current investigation, we show that RIIβ -/- mice also display increased NPY 
immunoreactivity in the nucleus accumbens (NAc) core and striatum relative to RIIβ 
+/+ mice. Further, in the NAc core of DBA/2J mice, viral-vector-mediated constitutive 
secretion of NPY (rAAV-FIB-NPY) promoted enhanced ethanol-induced locomotor 
activation while infusion of a separate viral vector, which blunts endogenous NPY 
signaling via agonist activity at the Y2 presynaptic autoreceptors, reduced ethanol-
induced locomotor activity relative to control-treated mice. On the other hand, rAAV-
FIB-NPY transduction in the striatum attenuated ethanol-induced locomotor 
iv 
 
sensitization suggesting that the role of NPY in the modulation of ethanol-induced 
locomotor behaviors is brain-region dependent. Interestingly, NPY -/- mice displayed 
a reduction in ethanol-induced locomotor activation and sensitization while mice 
lacking the NPY Y1 receptor (NPY Y1 -/- mice) exhibited enhanced ethanol-induced 
behavioral sensitization relative to respective wildtype controls. Taken together, 
these data establish a role for NPY signaling in modulating the locomotor stimulating 
effects of ethanol and/or ethanol-induced behavioral sensitization.  
The final set of experiments attempted to expand the current knowledge of 
the role of amygdalar NPY signaling in ethanol consumption, in both ethanol-
dependent and non-dependent mice. To that end, C57BL/6J mice were given 
amygdalar infusion of the rAAV-FIB-NPY vector and were exposed to either a long 
history of chronic ethanol consumption or intermittent cycles of ethanol vapor and 
withdrawal. Results suggested that NPY signaling in the amygdala modulates 
ethanol consumption in mice with an extensive history of ethanol consumption.  
Overall, the experiments presented herein provide further evidence of the 
ability of NPY signaling, in specific brain regions, to modulate neurobiological 
responses to ethanol including ethanol-induced behavioral sensitization and ethanol 
consumption.  
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
  
 
 Ethyl alcohol (also known as ethanol) is one of the most widely available and 
commonly used psychoactive substances. It is produced by the fermentation of 
various fruits or grains and can be made into more concentrated solutions using a 
distillation process. Alcohol is classified as a central nervous system (CNS) 
depressant although it is known to exhibit multi-faceted properties. At low doses, 
alcohol transiently stimulates the CNS and can lower inhibitions. At moderate doses, 
ethanol progressively depresses body functions with high doses leading to sedation 
and possibly death (Julien, 2008). 
The production and consumption of alcoholic beverages have been 
documented throughout history and across all continents. Recently, studies using 
combined chemical and archeological approaches have shown that pieces of pottery 
found in China dating from as early as the Neolithic period (7000 B.C.) were used to 
prepare, store, and serve fermented beverages (McGovern et al., 2004). In America, 
alcoholic beverage consumption was so prevalent that by 1860, there were 1,138 
legally operating alcohol distilleries in the U.S. producing 88 million gallons of liquor 
per year (Nelson, 1995). Interestingly, taxes temporarily imposed on alcohol were 
used to help fund the War of 1812 and later to partially finance the Civil War under 
Abraham Lincoln (Nelson, 1995). Further, the early years of the 20th century saw 
 2 
even more drastic increases in American alcohol consumption with beer production 
nearly doubling between 1900 and 1913 (Blocker, 2006).  
However, leaders of the temperance movement had been attributing 
increasing poverty, unemployment, and crime to rising levels of drunkenness and 
eventually, enough support for the movement led Congress to ratify the 18th 
amendment to the United States Constitution in 1919. This amendment effectively 
prohibited the manufacture, transport, import, export, or sale of alcoholic beverages. 
During this time, there was a decrease in overall alcohol consumption from pre-
prohibition levels despite black market production of alcohol (Blocker, 2006). This 
era of prohibition lasted from 1920-1933 when the 18th amendment was repealed 
with the passage of the 21st amendment. It seems that voters were looking to help 
boost economic recovery in the midst of the Great Depression and therefore 
supported the repeal (Blocker, 2006). Currently, the sale and public consumption of 
alcoholic beverages in America is legal over the national minimum drinking age of 21 
years old.  
Alcohol’s popularity as an intoxicating agent has certainly not diminished in 
recent years. In fact, according to the National Survey on Drug Use and Health 
(NSDUH, 2003), approximately half of all Americans aged 12 or older (119 million 
people) report being current drinkers of alcohol, indicating consumption during the 
last month. Further, approximately 17.6 million Americans meet the diagnostic 
criteria for alcohol abuse or alcohol dependence (NESARC, 2002). According to the 
Diagnostic and Statistical Manual of Mental Disorders-IV, alcoholism is defined as a 
maladaptive pattern of alcohol consumption leading to clinically significant distress 
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or impairment (DSM-IV, 1994). It is characterized by progressive and persistent 
patterns of drinking involving a preoccupation with drinking, development of 
tolerance, appearance of physical withdrawal symptoms, and loss of control over 
drinking. 
 
Pharmacological Treatments of Alcoholism 
  
Historically, the available treatment for alcoholism depended upon the current 
dominating opinion as to the nature of the disorder. The moral model proposed that 
consumption of alcohol was a personal choice and therefore, people should just 
make the alternative choice not to drink if it was causing detriment to their lives. A 
second model, the temperance model, suggested that the addictive and destructive 
power of the drug was inherent in the drug itself. Therefore, the proposed treatment 
option needed to be personal moderation or complete abstinence from alcohol use. 
Most recently, the disease model of alcoholism has been advanced in the field. 
Originally proposed in 1960, it asserts that alcoholism, in a strict pharmacological 
sense, is a disease (Jellinek, 1960). Important to this discussion then is that this 
model provides an impetus for the understanding and treatment of alcoholism from 
an evidence-based, as opposed to an opinion-based perspective.  
With advanced knowledge of the disease has come a development of 
approved pharmacotherapies for alcoholism. However, alcoholism has many 
neurobiological and psychological underpinnings leading to the classification of 
separate subtypes of alcoholics (Jellinek, 1960). Type 1 alcoholics typically 
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demonstrate a loss of control over drinking. They develop the disease later in life 
and tend to exhibit co morbid psychological disorders, especially anxiety-related 
disorders. Type II alcoholics experience the onset of the disorder at an earlier age 
and are characterized by heightened impulsivity, spontaneous and persistent alcohol 
seeking, and an inability to abstain from alcohol use (Cloninger, 1987). These 
different classifications suggest that effective treatments for excessive alcohol use 
may require multiple approaches. Currently, there are three pharmacological agents 
for the treatment of alcoholism which have been approved by the Food and Drug 
Administration (FDA). These medications have shown some promise in helping 
alcoholics to reduce their drinking, decrease craving, avoid relapse to heavy 
drinking, and achieve and maintain abstinence. 
 
Disulfiram (Antabuse) 
Disulfiram was the first drug to be approved and has been marketed in the 
United States since the 1940s (Tambour & Quertemont, 2007). It is an irreversible 
inhibitor of aldehyde dehydrogenase, a crucial enzyme in the normal breakdown of 
alcohol, allowing for an accumulation of acetaldehyde following ethanol intake (Abe, 
Yamaguchi, Sugiura, & Saito, 1999). Excessive acetaldehyde then manifests 
aversive symptoms such as palpitations, flushing, nausea, vomiting, headache, 
shortness of breath, hypotension, and tachycardia (Hald & Jacobsen, 1948; 
Johnsen, Stowell, & Morland, 1992). Therefore, disulfiram has been used as an 
aversion therapy under the hypothesis that alcoholics will avoid consuming alcohol 
after disulfiram administration in order to avoid the unpleasant side effects. Results 
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from the first randomized clinical trial suggest that disulfiram treatment does reduce 
the total number of days the patient drinks but does not sustain total abstinence from 
alcohol (Fuller et al., 1986). However, the treatment may have been more effective if 
compliance with the drug administration was more closely supervised (Chick, 1998). 
Furthermore, there are potentially life-threatening adverse effects associated with 
ethanol use in the presence of disulfiram including rare instances of hepatitis, 
peripheral neuropathy, and neuropsychiatry complications which have further limited 
the use of this drug in the treatment of alcoholism (Chick, 1999).  
 
Naltrexone (Depade, ReVia) 
Naltrexone is a partially-selective μ opioid receptor antagonist which has 
shown promise for the treatment of alcoholism. It is thought that antagonism of the 
opioid system prevents the ethanol-induced stimulation of dopamine release in the 
nucleus accumbens thereby reducing the rewarding properties of alcohol (Di Chiara, 
Acquas, & Tanda, 1996; Kato, 2008). Consistently, naltrexone administration has 
been shown to reduce alcohol intake, decrease craving, and maintain abstinence in 
alcohol dependent subjects (Anton, 2008; O'Malley, Krishnan-Sarin, Farren, Sinha, 
& Kreek, 2002; Volpicelli et al., 1997). Specifically, naltrexone-treated patients 
reported a significantly lower urge to drink than placebo-treated subjects (O'Malley et 
al., 2002). Further, naltrexone treatment was associated with a reduced number of 
drinks per day and attenuated risk of relapse during a 12-week double-blind placebo 
controlled trial of daily naltrexone administration (50 mg). In fact, only 23% of the 
naltrexone-treated subjects reached criteria for relapse to heavy drinking while 54% 
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of placebo-treated subjects relapsed (Volpicelli, Alterman, Hayashida, & O'Brien, 
1992). However, naltrexone treatment is not without side effects as administration is 
associated with an increase in dizziness, nausea, and weight loss compared to 
placebo control groups (O'Malley et al., 1992).  
 
Acamprosate (Campral)  
In 2004, the FDA approved acamprosate for the treatment of alcohol 
dependence specifically in patients who are currently alcohol free and seek to 
remain abstinent. Acamprosate is thought to work by reducing the negative 
symptoms that occur amidst a lengthy abstinence, such as anxiety and insomnia 
(Chick, Howlett, Morgan, & Ritson, 2000; Mason & Crean, 2007). While its 
mechanism of action is not completely clear, recent evidence suggests that 
acamprosate primarily attenuates excitatory glutamatergic neurotransmission, acting 
as an antagonist at the metabotropic glutamate receptor, subtype 5 (mGluR5) (De 
Witte, Littleton, Parot, & Koob, 2005; Spanagel & Zieglgansberger, 1997). 
Importantly, acamprosate has been shown to selectively block dependence-induced, 
but not spontaneous ethanol consumption (Boismare et al., 1984; Le Magnen, Tran, 
Durlach, & Martin, 1987; Rimondini, Arlinde, Sommer, & Heilig, 2002). More 
recently, in an FDA-required evaluation of the effectiveness of acamprosate, daily 
administration in abstinent alcoholics doubled the likelihood of one year total 
abstinence compared to placebo with analysis of secondary measures indicating 
that subjects treated with acamprosate exhibited an increased time to relapse and 
were abstinent up to 38% more days during the study than those in the placebo-
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control group (Kranzler & Gage, 2008). However, the therapeutic effectiveness of 
acamprosate is limited by the currently prescribed acamprosate regimen which 
requires large doses on a strict schedule (333 mg, 3 times a day)  (Heilig & Egli, 
2006). Further, prominent adverse effects such as diarrhea, nervousness, and 
fatigue are experienced especially at higher doses (Johnson, 2008). 
 
Taken together, the approved pharmacotherapies show some promise for 
treating alcoholism, but no single medication works in every case or in every person. 
Specifically, naltrexone is seemingly more effective in the treatment of type II, early 
onset, alcoholism while acamprosate may be more beneficial in the latter onset type 
I alcoholics (Heilig & Egli, 2006). Although, recent clinical studies have indicated a 
much smaller effect size for the available treatments than originally suggested 
(Johnson, 2008). Additionally, widespread use of the available pharmacotherapies is 
impeded by a lack of confidence in their effectiveness, with addiction counselors and 
specialists only prescribing to very limited numbers of alcohol addicted patients 
(Heilig & Egli, 2006; Thomas & Miller, 2007). Therefore, much ongoing research is 
dedicated to the development of new pharmacological targets in animal models of 
alcoholism. 
 
Animal Models of Human Alcoholism 
 
Alcoholism is a chronic, progressive disorder characterized by a multitude of 
features and it is essential to recognize the various stages of the alcohol addiction 
cycle when developing new pharmacological targets for treating the disorder. 
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Therefore, it is necessary to establish tools by which to investigate the separate 
genetic, environmental, behavioral and/or neurobiological components of human 
alcohol use disorders. Animal models allow researchers to address the individual 
features of alcoholism in fully controlled experimental manipulations leading to a 
more precise development and testing of potential therapeutics. In order to be 
classified as an appropriate model of human alcoholism, animals should voluntarily 
consume ethanol, reach pharmacologically relevant blood ethanol concentrations 
(BECs), maintain these high BECs over a period of time, and display physical 
dependence (Cicero, 1979; Fadda & Rossetti, 1998).  
 
Voluntary ethanol consumption 
 The most commonly utilized model of human alcoholism in animals is referred 
to as voluntary ethanol consumption. In this model animals are given a choice 
between one bottle containing some concentration of an ethanol solution and 
another bottle containing water. Since alcohol is a caloric substance, food is 
available ad libitum so as to ensure that the animals are not drinking ethanol for the 
calories. Typically, the amount of fluid consumed in each bottle is measured and 
then a preference ratio is calculated by dividing the ethanol intake by the total fluid 
consumed. Furthermore, the calculated preference ratio can then be used to create 
selectively bred high and low ethanol preferring rat lines by breeding together those 
animals with the highest and lowest ethanol preferences over generations. These 
selectively bred strains include the Indiana Alcohol Preferring (P) and Alcohol-non-
preferring (NP) rats, the Alko-Alcohol (AA) and Alko-Nonalcohol (ANA) rats, the High 
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Alcohol Drinking (HAD) and Low Alcohol Drinking (LAD) rats, and the Sardinian 
Preferring (sP) and Sardinian Non-Preferring (sNP) lines (Colombo, 1997; Eriksson 
& Malmstrom, 1967; Li, Lumeng, & Doolittle, 1993). With prolonged access to free 
choice ethanol, the P rat will voluntarily consume up to 12 g of ethanol per kg of 
body weight and reach pharmacologically relevant blood ethanol concentrations 
(BECs) of 50-200 mg/dL during 24-hour free choice ethanol self administration (Li, 
Lumeng, McBride, & Waller, 1979; Murphy et al., 2002). Further, certain strains will 
display uncontrolled drinking as demonstrated by sustained high ethanol 
consumption even when simultaneously presented with a highly preferred palatable 
fluid or when quinine is added to the ethanol solution (Lankford, Roscoe, 
Pennington, & Myers, 1991; Spanagel, 2000).         
 
Ethanol dependence 
A common criticism of voluntary ethanol consumption procedures is that 
animals may not consume sufficient amounts of ethanol over a long enough period 
of time to achieve physiological dependence. In fact, C57BL/6 mice, a strain known 
for its high ethanol consumption, display only mild acute or chronic ethanol 
withdrawal responses (Crabbe, Young, & Kosobud, 1983; Metten & Crabbe, 1994; 
Metten et al., 1998). Further, male golden hamsters spontaneously consume large 
quantities of ethanol (up to 14 g/kg/day) but also have a heightened ethanol 
metabolism and therefore show no signs of a withdrawal syndrome after 3 or more 
months of ethanol consumption (McMillan, Ellis, Frye, & Pick, 1977). Therefore, 
procedures that support a physical withdrawal syndrome and/or mimic a progressive 
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enhancement of ethanol consumption have been developed in order to aid our 
understanding of and assess the viability of new pharmacological agents for the 
treatment of ethanol dependent individuals.   
 A first attempt at modeling ethanol dependence involved forced exposure to 
ethanol in a nutritionally complete liquid diet. In this model, animals are given access 
to ethanol diet and water, but not chow, ensuring that the ethanol is consumed as 
part of maintaining a nutritional balance and survival (Lieber & DeCarli, 1982; Miller, 
Goldman, Erickson, & Shorey, 1980). However, while rodents in this procedure are 
able to attain BECs in a pharmacologically relevant range, the blood ethanol 
concentrations can fluctuate between and within days due to factors such as sleep 
and feeding schedules since the rodents are ultimately in control of their own 
consumption (Rogers, Wiener, & Bloom, 1979). 
In order to more vigorously achieve and maintain precise blood ethanol levels 
in rodents throughout the day, a recent model of ethanol dependence utilizes chronic 
ethanol administration via ethanol vapor inhalation. In this model, rodents are 
exposed to ethanol via inhalation procedures whereby ethanol is volatized, mixed 
with air in specific amounts, and pumped into the chamber where the rodents are 
housed. Depending on the ethanol-air ratio, experimenters can specify the precise 
BECs maintained throughout the experimental procedure with a typical range of 150-
200 mg/dL. Recently it has been shown that repeated ethanol vapor exposures and 
acute withdrawals using this method can induce increased voluntary ethanol 
drinking, similar to the increases in drinking associated with human ethanol 
dependence (Finn et al., 2007; Lopez & Becker, 2005; Roberts, Heyser, Cole, 
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Griffin, & Koob, 2000). Specifically, C57BL/6J mice exposed to 2 cycles of repeated 
ethanol exposures and withdrawals displayed significantly increased consumption of 
a 15% ethanol solution over baseline levels and in comparison to air-exposed mice 
(Becker and Lopez, 2004).  
Importantly, several pharmacological compounds have been shown to reduce 
ethanol consumption in ethanol dependent animals while proving ineffective in 
altering ethanol consumption in non-dependent animals (Finn et al., 2007; Gilpin, 
Richardson, & Koob, 2008b; Gilpin, Stewart, & Badia-Elder, 2008c; Thorsell, 
Slawecki, & Ehlers, 2005). The ability of compounds to affect ethanol consumption 
differentially in non-dependent versus dependent animals is consistent with the 
allostatic theory of alcohol addiction proposed by Koob and colleagues (Koob, 2003; 
Koob & Le Moal, 2001). This theory posits that the exposure to repeated cycles of 
intoxication, abstinence, and relapse which occurs during the development of 
dependence leads to a dysregulation of the processes/neurotransmitter systems that 
maintain the homeostatic set point within the structures of the extended amygdala. 
These include the central nucleus of the amygdala, bed nucleus of the stria 
terminalis, and the shell region of the nucleus accumbens. Continued cycles of 
dysregulation within these systems and structures then lead to a modified, 
pathological allostatic set point in which the negative affect associated with ethanol 
withdrawal becomes increasingly heightened. The exaggerated negative affect then 
ultimately triggers relapse in dependent individuals thereby perpetuating the cycle of 
dependence. Therefore, pharmacological treatments aimed at reestablishing normal 
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neuronal transmission within the extended amygdala may be appropriate targets for 
treating neurobiological responses associated with ethanol dependence.  
 
Behavioral sensitization 
 Behavioral sensitization is defined as the long-lasting and progressive 
enhancement of the locomotor responses to repeated administration of a drug 
(Kalivas and Stewart, 1991). Importantly, this phenomenon is known to have explicit 
neurochemical correlates. Specifically, repeated use of addictive drugs is thought to 
usurp the dopaminergic neural circuitry typically involved in reward and motivation 
causing progressive and persistent neuroadaptations. This circuitry includes 
dopaminergic projections from the ventral tegmental area to the nucleus accumbens 
and amygdala, and from the substantia nigra to the striatum (Pierce & Kalivas, 1997; 
Robinson & Berridge, 2003; White & Kalivas, 1998). Neuroadaptations in this 
circuitry are thought to underlie the increasingly hypersensitized response to the 
drug (e.g., increased sensitivity to the locomotor stimulant effects of drugs) and 
drug-related stimuli and these hypersensitized responses are hypothesized to reflect 
the increased motivation to obtain the drug in theories such as the incentive-
sensitization theory of addiction proposed by Robinson and Berridge. Specifically, 
craving for/wanting of a drug sensitizes, or becomes more salient, with repeated 
exposure to the drug (1993). The pervasive neuroadaptive changes in this circuitry 
may explain why addicts crave drugs in general and why this drug craving persists 
even following a long-term abstinence period and in the face of strong negative 
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outcomes. Viewed this way, understanding the central pathways that modulate 
behavioral sensitization may provide insight into the mechanisms of addiction.  
 Modeling this phenomenon in the laboratory involves exposing animals to 
repeated administration of a drug. Original experiments involved intraperitoneal (i.p.) 
injections of saline given immediately preceding placement into a locomotor activity 
monitor in order to establish a baseline locomotor activity, followed by repeated 
injections of ethanol (i.p.) with activity monitoring to assess behavioral sensitization. 
More recent procedures involve establishing a locomotor activity baseline following 
saline injection and then an initial locomotor response to a low to moderate dose of 
ethanol. This is then followed by several daily injections of a higher dose of ethanol 
given in the homecage. On a final test day, animals are monitored for locomotor 
activity following an injection of the original low dose of ethanol.  The activity 
following the final ethanol injection is then compared to the initial ethanol response 
to determine the extent of ethanol-induced sensitization.  
 
Inbred and Genetically Modified Mice 
  
A common method of studying the contribution of specific genes to behavior 
is by utilizing inbred and genetically modified mouse strains in the paradigms 
discussed above. An inbred strain is defined as one that is produced using at least 
20 consecutive generations of sister x brother or parent x offspring matings (Jackson 
Labs). With this procedure, every mouse in a specific strain should be genetically 
identical to the others of that strain. Therefore, comparisons of different strains 
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known to express divergent phenotypes or differential responses could help to 
elucidate the neurobiological underpinnings of a certain behavior. For example, 
C57BL/6J mice are known to voluntarily consume greater than 10 g/kg/day of 
alcohol while DBA/2J mice consume less than 2 g/kg/day (Belknap, Crabbe, & 
Young, 1993; Yoneyama, Crabbe, Ford, Murillo, & Finn, 2008). Therefore, 
experiments comparing these inbred strains could further our understanding of the 
genes that play a role in the neurobiological effects of ethanol.  
To more directly elucidate the genetic determinants of complex behaviors in 
vivo, a large number of genetically manipulated knockout, knockin, and transgenic 
mouse strains have been developed. These viable mutant mice are generated by 
using selective gene targeting in mouse embryonic stem cells allowing for the 
removal or overexpression of a specific gene or set of genes (Stephens, Mead, & 
Ripley, 2002). The ability to manipulate the specific genetic makeup of organisms 
has provided a novel means of investigating the neurobiological mechanisms 
underlying a multitude of behaviors. By observing phenotypic differences between 
genetically modified mice and their non-manipulated littermate controls, researchers 
can begin to infer the potential function of a specific gene. In this way, researchers 
have been able to implicate several genes in ethanol-related behaviors including, but 
certainly not limited to, the genes encoding the neuropeptide Y gene and a specific 
subunit of protein kinase A. 
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The Role of Neuropeptide Y in Ethanol-Related Phenotypes 
 
Neuropeptide Y (NPY) is a 36 amino acid neuromodulator with activity in a 
number of brain regions including the amygdala, caudate putamen, hippocampus, 
and hypothalamus (Berglund, Hipskind, & Gehlert, 2003; Colmer & Wahlestedt, 
1993; Gray & Morley, 1986). There are currently 5 known receptor subtypes in the 
mouse: Y1, Y2, Y4, Y5, and Y6 of which only the Y1, Y2, and Y5 receptors are 
expressed centrally. All of the NPY receptors couple to Gi/o proteins which inhibit the 
production of cyclic adenosine monophosphate (cAMP) (Palmiter, Erickson, 
Hollopeter, Baraban, & Schwartz, 1998). Thus, NPY has been implicated in a wide 
range of biological functions with recent evidence suggesting a role for NPY in the 
neurobiological effects of ethanol (Clark, Kalra, Crowley, & Kalra, 1984; Hansel, 
Eipper, & Ronnett, 2001; Heilig et al., 1993; Pandey, Carr, Heilig, Ilveskoski, & 
Thiele, 2003a; Thiele & Badia-Elder, 2003; Woldbye, Madsen, Larsen, Mikkelsen, & 
Bolwig, 1996).  
Specifically, evidence suggests that there is an inverse relationship between 
NPY levels and voluntary ethanol consumption. Consistent with this theory, 
selectively bred alcohol preferring (P) and High Alcohol Drinking (HAD) rats have 
low levels of NPY in the amygdala as compared to their low alcohol consuming 
counterparts (Hwang, Zhang, Ehlers, Lumeng, & Li, 1999). Further, the high levels of 
ethanol consumption in P and HAD rats are reduced by ventricular administration of 
NPY suggesting that NPY can rescue the increased ethanol consumption 
characteristic of these strains (Badia-Elder, Stewart, Powrozek, Murphy, & Li, 2003; 
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Badia-Elder et al., 2001; Gilpin, Stewart, Murphy, Li, & Badia-Elder, 2003). Similarly, 
a study utilizing genetically modified mice indicated that mice lacking the NPY gene 
(NPY -/- mice) consumed higher amounts of ethanol while NPY overexpressing 
(NPY-OX) mice drank less ethanol than their wildtype littermate controls (Thiele, 
Marsh, Ste. Marie, Bernstein, & Palmiter, 1998). Interestingly, NPY-/- mice on a 
mixed C57BL/6J X 129/SvEv genetic background also displayed an increased 
sensitivity to the locomotor stimulant effects of ethanol (Thiele, Miura, Marsh, 
Bernstein, & Palmiter, 2000a). Taken together, these data suggest a role for NPY in 
ethanol-related phenotypes.  
 
The Role of Protein Kinase A in Ethanol-Related Phenotypes 
 
Protein kinase A (PKA) is a haloenzyme that consists of a regulatory subunit 
homodimer and two catalytic subunits (Brandon et al., 1998). In the mouse, PKA 
consists of four regulatory subunits (RIα, RIβ, RIIα, and RIIβ) and two catalytic 
subunits (Cα and Cβ) (Brandon et al., 1998). PKA is activated by the binding of 
cyclic adenosine monophosphate (cAMP) to the regulatory subunit, which causes 
the release of the catalytic and RIIβ subunits (Dohrman, Chen, Gordon, & Diamond, 
2002). The catalytic subunit is then free to phosphorylate nearby substrates or both 
subunits can translocate to the nucleus to regulate gene expression. This 
cAMP/PKA signal transduction pathway is either activated or inhibited via G-protein 
coupled receptor binding to adenyl cyclase (AC). The activation of AC then 
increases or decreased cAMP-dependent PKA activity, respectively (Dohrman et al., 
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2002). Since numerous neurotransmitters, neuromodulators, and hormones function 
by modulating G-protein coupled receptors, the cAMP/PKA signal transduction 
pathway is involved in a vast array of physiological functions. Recently, this pathway 
has been shown to be involved in neurobiological responses to ethanol. Importantly, 
ethanol administration is known to stimulate cAMP-PKA signaling in the central 
nervous system by allowing the translocation of the catalytic and regulatory subunits 
to the nucleus where they can exert effects on downstream signaling (Asyyed, 
Storm, & Diamond, 2006; Dohrman et al., 2002). Behaviorally, in a model of reduced 
cAMP-stimulated PKA activity, mice devoid of the RIIβ subunit of PKA (RIIβ -/- mice) 
consume higher amounts of ethanol and are less sensitive to the sedative effects of 
ethanol than wildtype littermate controls (Thiele et al., 2000b). Further, more recent 
studies have shown that RIIβ -/- mice exhibit increased ethanol-induced locomotor 
sensitization following repeated ethanol administration compared to wildtype mice 
(Fee et al., 2006). 
 
Recombinant Adeno-Associated Viral Vectors 
 
Recently a viral vector platform has been developed that supports in vivo 
expression and also allows constitutive secretion of a gene product. Using adeno-
associated viral (AAV) vectors, Haberman et al. (2003) developed a novel gene 
therapy platform where neuroactive peptide expression was combined with 
constitutive secretion from the transduced cell. When the secretion signal sequence 
from the constitutively secreted laminar protein fibronectin (FIB) preceded the coding 
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sequence for the neuroactive peptide, galanin, expression and constitutive secretion 
of galanin was obtained (Haberman, Samulski, & McCown, 2003). Moreover, 
sufficient constitutive secretion was obtained in vivo to significantly alter focal 
seizure sensitivity, seizure-induced cell death and kainic acid-induced generalized 
seizures (Haberman et al., 2003; McCown, 2006). In marked contrast, expression of 
galanin without the fibronectin secretory signal sequence had no influence on 
seizures or cell death. Recently, Foti et al. (2007) have shown that by using the 
same gene therapy approach, expression and constitutive secretion of either NPY or 
the NPY fragment, NPY13-36, also dramatically attenuates kainic acid-induced 
seizure activity. Given the ability of AAV to support long-term, stable gene 
expression in the CNS (Klein et al., 2002; McCown, Xiao, Li, Breese, & Samulski, 
1996), this novel gene therapy approach provides an excellent tool to express and 
constitutively secrete NPY or the NPY13-36 fragment in the brain.   
 
Goals of the Dissertation 
  
The main goal of this dissertation is to further investigate the roles of NPY 
and PKA in neurobiological responses to ethanol. First, chapter 2 further 
investigated the relationship between NPY and PKA in the modulation of 
neurobiological responses to ethanol and the hypothesis that PKA drives NPY 
synthesis. To that end, NPY mRNA and protein levels were examined in RIIβ -/- and 
RIIβ +/+ mice following acute or repeated ethanol administration. Chapter 3 
assessed the role of NPY in ethanol-induced locomotor sensitization via multiple 
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strategies. Recombinant adeno-associated viral vectors were used to express and 
secrete NPY and NPY13-36 in the NAc core and/or striatum of DBA/2J mice. Further, 
ethanol-induced locomotor sensitization was investigated in mutant mice lacking the 
NPY or NPY Y1 receptor. Finally, chapter 4 attempted to further elucidate the role of 
NPY in voluntary ethanol consumption using recombinant adeno-associated viruses 
in C57BL/6J mice with an extended history of ethanol consumption or exposure to 
intermittent cycles of vapor exposure and withdrawal. These studies expand our 
knowledge of the roles that NPY and PKA play in modulating the behavioral and 
neurobiological features of alcoholism.     
 
  
 
 
 
 
CHAPTER 2 
 
MUTANT MICE LACKING THE RIIβ SUBUNIT OF PROTEIN KINASE A (PKA) 
EXHIBIT INCREASED NEUROPEPTIDE Y (NPY) MESSENGER RNA AND 
PROTEIN IN SPECIFIC BRAIN REGIONS 
 
 
Introduction 
 
Neuropeptide Y (NPY) and Protein Kinase A (PKA) are involved in a vast 
array of biological functions (Clark et al., 1984; Hansel et al., 2001; Heilig et al., 
1993; Woldbye et al., 1996). More recently, NPY and PKA have both been 
implicated in the neurobiological effects of ethanol (Fee et al., 2004; Pandey, 2003; 
Thiele & Badia-Elder, 2003; Thiele, Sparta, Hayes, & Fee, 2004b; Thiele et al., 
2000b; Wand, Levine, Zweifel, Schwindinger, & Abel, 2001). A role for NPY in 
ethanol consumption has been firmly established. Specifically, selectively bred 
alcohol-preferring (P) rats and high alcohol drinking (HAD) rats have low levels of 
NPY in multiple brain regions as compared to their respective low alcohol drinking 
counterparts, and ventricular administration of NPY in these rat lines can reduce 
their characteristic high ethanol consumption (Badia-Elder et al., 2001; Ehlers et al., 
1998; Gilpin et al., 2003; Hwang et al., 1999). Further, in genetically modified mice, 
mice lacking the NPY gene (NPY -/- mice) consume higher amounts of ethanol while 
NPY overexpressing mice (NPY-OX) consume less ethanol than their respective 
wildtype littermate controls (Thiele et al., 1998). Taken together, these data suggest 
an inverse relationship between NPY and ethanol consumption. NPY has also been 
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implicated in other ethanol-related phenotypes. Specifically, NPY -/- mice maintained 
on a mixed C57BL/6Jx129/SvEv genetic background displayed increased sensitivity 
to the stimulation of locomotor behavior caused by intraperitoneal (i.p.) injection of a 
low dose of ethanol. Interestingly, these NPY -/- mice were also resistant to the 
sedative effects of a high dose of ethanol (Thiele et al., 2000a). However, the 
mechanism by which NPY modulates ethanol-induced locomotor activity and/or 
behavioral sensitization requires further characterization. 
Several lines of evidence suggest a role for protein kinase A (PKA) in ethanol-
related behaviors. First, ethanol is known to stimulate cyclic adenosine 
monophosphate (cAMP)-PKA signaling in the central nervous system (Asyyed et al., 
2006). In vivo evidence suggests that cAMP signaling is upregulated following 
ethanol exposure (Li, Li, & Yuan, 2003). Specifically, chronic ethanol exposure 
allows for the sustained translocation of the catalytic and regulatory II subunits of 
PKA to the nucleus where they can exert effects on downstream signaling including 
CRE-mediated gene expression (Dohrman et al., 2002; Dohrman, Diamond, & 
Gordon, 1996). Genetically modified mice which lack one of the regulatory subunits 
of PKA (RIIβ -/- mice) display decreased cAMP-stimulated PKA activity in several 
critical brain regions known to be involved in responses to drugs of abuse (Brandon 
et al., 1998). These regions include the striatum, nucleus accumbens, amygdala, 
and hypothalamus. Interesting, RIIβ -/- mice consistently consume higher amounts of 
ethanol and exhibit reductions in their sensitivity to the sedative properties of ethanol 
as compared to their wildtype littermate controls (Fee et al., 2004; Thiele et al., 
2000b). Consistently, Sprague-Dawley rats infused with a PKA inhibitor, KT-5720, 
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show dose-dependent decreases in ethanol-induced sleep time as assessed by a 
loss of righting reflex (Lai, Kuo, & Lin, 2007). 
Importantly, recent evidence suggests that PKA promotes NPY synthesis. As 
previously described, the binding of a G-protein to adenyl cyclase allows for changes 
in cyclic adenosine monophosphate, which in turn affects PKA activity (Dohrman et 
al., 2002). The changes in gene transcription that result from manipulations of this 
pathway occur via the cAMP-responsive element binding (CREB) protein such that 
PKA regulates CREB via phosphorylation, inducing a conformational change in the 
CREB protein (Pandey, Mittal, Lumeng, & Li, 1999). The conformational changes 
influence the CREB protein binding to CRE-binding domains (Ginty, Bading, & 
Greenberg, 1992). Interestingly, NPY is one of the cAMP-inducible genes which 
contains a CRE-binding domain and is therefore regulated by the CREB gene 
transcription factor (Pandey, Roy, Zhang, & Xu, 2004). Consistently, central infusion 
of the PKA inhibitor, Rp-cAMP, decreased the expression of NPY in the amygdala of 
Sprague-Dawley rats while amygdalar infusion of Sp-cAMP, a PKA activator, 
rescued the reductions in NPY mRNA and protein observed following ethanol 
withdrawal (Pandey, Roy, & Zhang, 2003b; Zhang & Pandey, 2003). Furthermore, 
mice with a partial deletion of the cAMP-responsive element binding (CREB) protein 
gene display decreased levels of CREB, phosphorylated CREB (pCREB), and NPY 
throughout the brain compared to controls (Pandey et al., 2004). Consistently, these 
CREB haplodeficient mice (CREB +/-) also display a higher preference for ethanol 
than their littermate controls (Pandey et al., 2004).  
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Because PKA signaling stimulates NPY synthesis, and because we have 
found that RIIβ -/- mice show altered neurobiological responses to ethanol, we 
determined if RIIβ -/- mice have decreased levels of NPY mRNA and/or protein 
compared to RIIβ +/+ mice at baseline and/or in response to ethanol administration. 
To that end, we compared NPY levels between RIIβ -/- and RIIβ +/+ mice in brain 
regions known to be involved in modulating neurobiological responses to ethanol 
including the hypothalamus, brainstem, nucleus accumbens, striatum, and 
amygdala.  
 
 Methods 
 
Animals 
 
RIIβ -/- mice were created via homologous recombination that disrupted the 
RIIβ gene in embryonic stem cells of 129/SvJ mice (Brandon et al., 1998). Chimeras 
were bred with C57BL/6J mice to obtain heterozygotes which were then 
backcrossed over eight generations onto a pure C57BL/6J background as previously 
described (Fee et al., 2006). For the first experiment, we used 40 male and female 
RIIβ -/- and RIIβ +/+ littermate mice at approximately 6-9 months of age. Since these 
animals are bred in house, we used both males and females to increase our subject 
numbers in order to boost statistical power and to assess potential sex-genotype 
interactions in our dependent measures. In the second experiment, we used 50 male 
RIIβ -/- and RIIβ +/+ littermate mice at 3-5 months of age. The RIIβ -/- mice weighed 
significantly less than RIIβ +/+ at the beginning of each of the experiments (24.63 ± 
0.49 vs. 26.98 ± 0.79 grams [F(1,37) = 6.197; p = 0.017] and 23.72 ± 0.44 vs. 25.33 ± 
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0.32 grams [F(1,48) = 8.720; p = 0.005], respectively). The reduced body weight 
observed in RIIβ -/- mice is related to reduced white adipose tissue production as 
described previously (Cummings et al., 1996). All mice were housed individually in 
polypropylene cages with corncob bedding (Teklad, Madison, WI) and had ad libitum 
access to standard rodent chow (LabDiet, Brentwood, MO) and water. The colony 
room was maintained at 22ºC with a 12 hour: 12 hour light: dark cycle. All 
procedures used in the present studies were conducted in compliance with the 
National Institute of Health guidelines and each protocol has been approved by the 
University of North Carolina Institutional Animal Care and Use Committee (IACUC). 
 
Assessment of NPY mRNA Levels using Reverse Transciptase Polymerase 
Chain Reaction (RT-PCR) in RIIβ -/- and RIIβ +/+ mice 
 
Ethanol Exposure 
 All mice received a single intraperitoneal (i.p.) injection of either saline (N=14) 
or one of two doses of ethanol, 1.5 g/kg or 4.0 g/kg ethanol (20% w/v mixed in 
isotonic saline; in 7.5 ml/kg or 20 ml/kg volumes; N=13 and 12, respectively). Mice 
were removed from their cages, given the injection of drug or vehicle, and then were 
immediately returned to their cage. 
 
Tissue Collection 
After one hour (Chan & Sawchenko, 1998; Thorsell et al., 1998), animals 
were sacrificed via rapid decapitation, their brains were rapidly removed, and the 
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brainstem, hypothalamus, and nucleus accumbens were removed from each mouse 
via microdissection. Brain regions were separately homogenized and total RNA was 
extracted from each brain region using Tri-Reagent (Molecular Research Center, 
Inc., Cincinnati, Ohio, USA). The RNA was then quantified spectrophotometrically 
(GeneQuant II, Pharmacia-Biotech, Piscataway, N.J., USA). 
 
Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR) 
Reverse transcription was performed utilizing the protocol available in the 
advantage RT-for-PCR kit from Clontech (Palo Alto, CA). PCR amplifications were 
performed using the LightCycler instrument and the Fast Start DNA Master SYBR 
Green I Real-Time PCR Kit (Roche, Indianapolis, Ind., USA). A master mix 
containing all reaction components was prepared and each reaction used 20 μl of 
mix in glass capillary tubes specifically designed for use in the LightCycler system. 
The Nucleic Acids Core Facility (Lineberger Cancer Center, UNC-Chapel Hill) 
synthesized the PCR primer set for Neuropeptide Y. Copy numbers were generated 
from an external standard curve using six concentrations of a standard. 
Amplifications were carried out for 40 cycles, and curves showing fluorescence at 
each cycle were determined by the computer software (Roche). Samples were pre-
incubated for 10 min at 95°C to activate the Fast-Start Taq DNA polymerase. The 
cycle temperatures were 95, 60, and 72°C for the denaturing, annealing, and 
extending, respectively. The cycle times were 15, 5, and 25 s for the denaturing, 
annealing, and extending, respectively. Fluorescence level was determined at the 
end of the extending phase for each cycle of PCR. The analysis of the fluorescence 
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level in standards and samples over the course of 40 cycles was used to derive the 
number of copies of the target molecule in each sample. The data are expressed as 
a copy number of NPY (per 10 ng cDNA) based on the standard curve using the 
Lightcycler software (Roche). Furthermore, to confirm the nature of amplification 
product, a melt curve analysis was conducted after the final PCR cycle. This 
analysis involved denaturing the products by slowly heating them to 95°C, during 
which, fluorescence is continuously measured. This protocol was established in the 
laboratory of Dr. Donald T. Lysle (Lysle & Ijames, 2002; Szczytkowski & Lysle, 
2007). 
 
Data Analysis 
All data are represented as mean ± standard error of the mean (SEM). Data 
were analyzed using analysis of variance (ANOVA) and significance was accepted 
at p < 0.05 (two-tailed). 
 
Assessment of NPY Protein Levels Using Immunohistochemistry in RIIβ -/- and 
RIIβ +/+ mice 
 
Ethanol Exposure 
All mice received an intraperitoneal (i.p.) injection of either 2.0 g/kg ethanol 
(20% w/v in 0.9% NaCl) or equivolume isotonic saline on each of 5 consecutive days 
according to the protocol detailed in Table 2.1 (all injections were administered in a 
volume of 10 ml/kg). Briefly, the control group received 5 separate saline injections 
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(N=16), the acute ethanol group received 4 saline injections followed by a final 
ethanol injection on Day 5 (N=17), and the repeated ethanol group received 5 
ethanol injections (N=16) in their homecages.  
 
Tissue Collection 
Precisely two hours after the final injection (Ogilvie, Lee, & Rivier, 1998), 
animals were anesthetized and perfused transcardially with 0.1 mM phosphate-
buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde in buffered saline. 
The brains were collected and post-fixed in paraformaldehyde for 24 hours at 4°C 
and then sliced into 40 μm sections using a vibrotome.  
 
NPY Immunohistochemistry 
Tissue slices containing the nucleus accumbens, striatum, amygdala, and 
paraventricular nucleus of the hypothalamus (PVN) were washed in 0.1 M 
phosphate buffered saline and then blocked in a solution containing 10% goat serum 
and 0.1% Triton X-100 for 1 hour. The slices were then incubated with rabbit anti-
NPY antibody (Peninsula Laboratories, San Carlos, CA; 1:1000) and 3% goat serum 
for approximately 72 hours at 4°C. After multiple washes in PBS, slices were 
incubated with biotinylated secondary antibody from the VectaStain rabbit ABC kit 
(Vector Laboratories, Burlingame, CA) and 3% goat serum for 1 hour at room 
temperature. Following several PBS washes, tissue slices were transferred to the 
VectaStain ABC reagent mixture and allowed to process for 1 hour. Slices were then 
stained using the DAB method (Vector Laboratories, Burlingame, CA) with 0.0063% 
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H2O2, 0.05% DAB, 0.0075% NiAmSO4, and 0.005% CoCl2. As a control to assess 
potential non-specific staining, some sections were run through the assay without 
primary or without secondary antibody. In the absence of primary or secondary 
antibody, no staining occurred verifying the specificity of staining. Slices were then 
mounted onto microslides using ShurMount mounting media (Durham, NC). Images 
were visualized using a Nikon Digital Sight DS-U1 camera attached to a Nikon 
Eclipse E400 microscope (Melville, NY) with 4X, 10X, and 20X objectives. Image J 
(NIH, Bethesda, MD) software was used to process background (non-cellular 
regions or corpus colossum) and signal (cell body or processes) intensities and data 
were presented as background-corrected standardized image densities for each 
brain region. 
 
Data Analysis 
All data are represented as mean ± standard error of the mean (SEM). Data 
were analyzed using analysis of variance (ANOVA) and LSD tests were performed 
for post-hoc analyses of planned comparisons. Significance was accepted at p < 
0.05 (two-tailed). 
 
Results 
Figure 2.1 shows the expression of NPY mRNA in the nucleus accumbens 
(A), hypothalamus (B), and brainstem (C) at baseline and in response to acute low 
or high dose ethanol administration. A three-way (sex x genotype x ethanol 
treatment) ANOVA of central NPY copy numbers in each brain region revealed a 
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significant main effect of genotype in the hypothalamus [F(1,27) = 4.40; p = 0.045], 
indicating that RIIβ -/- mice exhibit significantly higher levels of NPY mRNA than the 
RIIβ +/+ mice. However, there were no significant effects of sex [F(1,27) = 0.53; p = 
0.471] or ethanol treatment [F(2,27) = 1.00; p = 0.381], nor were there significant 
interaction effects from samples collected in the hypothalamus. Further, statistical 
analysis indicates no significant effects of sex, genotype, ethanol treatment, or 
interaction effects in data sets collected from the nucleus accumbens or brainstem. 
(See table 2.2 for complete results). 
Representative photomicrographs and quantification of NPY immunoreactivity 
(IR) in the nucleus accumbens (NAc) of RIIβ -/- and RIIβ +/+ are depicted in Figure 
2.2. Relative to RIIβ +/+ mice, RIIβ -/- mice displayed higher NPY IR in the core of 
the NAc (Figure 2.2C), as confirmed by the two-way (genotype x ethanol treatment) 
ANOVA which revealed a significant main effect of genotype [F(1,35) = 6.85; p = 
0.014]. Importantly, genotype differences in the nucleus accumbens were specific to 
the core as RIIβ +/+ and RIIβ -/- mice displayed similar NPY IR in the shell of the 
NAc [F(1,35) = 0.79; p = 0.381] (Figure 2.2D). Further, there was no significant effect 
of ethanol treatment or genotype x ethanol treatment interaction in either the core or 
the shell of the nucleus accumbens. See table 2.3 for complete results.  
Representative photomicrographs and quantification of NPY immunoreactivity 
in the striatum of RIIβ -/- and RIIβ +/+ can be seen in Figures 2.3 and 2.4, 
respectively. RIIβ -/- mice displayed higher NPY IR in the ventromedial [F(1,35) = 
15.67; p < 0.001] and ventrolateral [F(1,35) = 8.35; p = 0.007] subregions of the 
striatum relative to wildtype littermate controls (Figure 2.5) as indicated by two-way 
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ANOVAs which revealed significant main effects of genotype in each region. The 
genotype effect is sub-region specific as there were no significant effects of 
genotype in the dorsomedial or dorsolateral striatum. Interestingly, a two-way 
ANOVA also revealed a significant effect of ethanol treatment in the ventromedial 
[F(2,35) = 3.90; p =0.032] and ventrolateral [F(2,35) = 4.91; p = 0.015] subregions of the 
striatum (Figure 2.6) without indicating any genotype x ethanol treatment 
interactions. Post hoc LSD tests performed on the ethanol treatment main effect in 
these regions revealed that acute ethanol-treated mice displayed significantly lower 
NPY immunoreactivity than saline treated mice in both the ventromedial (p = 0.050) 
and ventrolateral (p = 0.034) subregions of the striatum. The ethanol treatment effect 
is also sub-region specific as indicated by a lack of significant differences in the 
dorsomedial or dorsolateral striatum. See table 2.3 for complete results. 
Two-way (genotype x ethanol treatment) ANOVAs further indicate brain 
region specificity in that there were no significant effects of genotype, ethanol 
treatment, or the interaction in the central nucleus of the amygdala, the basolateral 
amygdala, or the paraventricular nucleus of the hypothalamus (Table 2.3). 
  
Discussion 
 In this study, we assessed the levels of NPY mRNA and protein in RIIβ -/- and 
RIIβ +/+ mice at baseline and in response to ethanol administration. We report that 
RIIβ -/- mice display site specific increases in NPY mRNA in the hypothalamus and 
in NPY immunoreactivity in the nucleus accumbens core, ventromedial striatum, and 
ventrolateral striatum compared to RIIβ +/+ mice. Further, administration of an acute 
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dose of ethanol site-specifically reduced NPY immunoreactivity in the ventromedial 
and ventrolateral striatum.    
Contrary to our hypothesis, current results indicate an increase in 
hypothalamic NPY mRNA in RIIβ -/- mice as compared to RIIβ +/+ mice. However, 
previous observations may explain these results. Several lines of research suggest 
that hypothalamic NPY signaling is involved in food intake and energy homeostasis 
(Arora & Anubhuti, 2006; Berglund et al., 2003; Bi, 2007; Bi, Robinson, & Moran, 
2003; Hwa et al., 1999; Slawecki, Betancourt, Walpole, & Ehlers, 2000). Specifically, 
increased metabolic demand is known to result in an upregulation of NPY in the 
hypothalamus (Dube, Kalra, & Kalra, 2007). For instance, rats with a manipulated 
energy balance due to chronic food restriction show a 2-fold increase in NPY in the 
hypothalamus which is increased as much as 5-fold if the food-restricted animals are 
further challenged by forced wheel running (de Rijke, Hillebrand, Verhagen, Roeling, 
& Adan, 2005). Importantly, RIIβ -/- mice exhibit a lean phenotype, nocturnal 
hyperactivity, and increased resting metabolic rate compared to wildtype controls 
(McKnight et al., 1998; Newhall, Cummings, Nolan, & McKnight, 2005). Therefore, it 
is possible that a modified energy balance in these animals leads to the 
hypothalamic upregulation of NPY mRNA seen in RIIβ -/- mice compared to 
wildtypes. 
Furthermore, RIIβ -/- mice exhibited an enhancement of NPY signaling in the 
NAc core and the striatum as compared to RIIβ +/+ mice despite predictions to the 
contrary. Predictions were based on the knowledge that disruption of the RIIβ 
regulatory subunit of PKA decreases cAMP-stimulated PKA activity ultimately 
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leading to decreased CRE-mediated gene expression (Brandon et al., 1998). 
However, more recent evidence suggests that there is an increase in basal levels of 
PKA activity in RIIβ -/- mice. Specifically, ablation of the RIIβ subunit allows for the 
release of the active catalytic subunit, Cα, in brain regions where RIIβ is usually 
highly expressed, including the nucleus accumbens and striatum (Cadd & McKnight, 
1989; Czyzyk, Sikorski, Yang, & McKnight, 2008). The unbound catalytic subunit is 
free to translocate to the nucleus yielding an increase in basal PKA activity (Czyzyk 
et al., 2008). Interestingly, the nuclear presence of the Cα subunit is shown to be 
accompanied by a persistent phosphorylation of CREB leading to a striking 
enhancement of CRE-mediated gene expression (Constantinescu, Gordon, & 
Diamond, 2002). Consistently, a recent experiment conducted in male Wistar rats 
indicates that ethanol vapor exposure is associated with an increase in nuclear PKA 
inhibition which coincides with a decrease in NPY expression in select brain regions 
(Repunte-Canonigo, Lutjens, van der Stap, & Sanna, 2007). Thus, increased basal 
PKA activity in the RIIβ -/- mice may account for the increased levels of NPY in 
specific brain regions supporting the idea that PKA promotes NPY synthesis.  
The nucleus accumbens shell and amygdala are both integral regions in the 
mesolimbic dopaminergic pathway known to be involved in reward, motivation, and 
the reinforcing properties of drugs of abuse (Kalivas & Nakamura, 1999; Koob, 1992; 
Nestler, 2001). Further, disruptions in NPY signaling in this pathway are postulated 
to play a role in the development of ethanol dependence (Koob, 2003). Interestingly, 
RIIβ -/- mice consume higher amounts of ethanol, are less sensitive to the sedative 
effects of ethanol, and exhibit increased ethanol-induced locomotor sensitization 
 33 
following repeated ethanol administration compared to wildtype littermate controls 
(Fee et al., 2006; Fee et al., 2004; Thiele et al., 2000b). However, RIIβ -/- mice did 
not display any alteration in NPY signaling in these regions. Therefore, NPY 
signaling in the nucleus accumbens shell and the amygdala may not play a role in 
the increased ethanol consumption in RIIβ -/- mice. However, as with any mutant 
mouse model, compensatory developmental changes in PKA subunit expression, 
including a known upregulation of the RIα subunit in RIIβ -/- mice (Amieux et al., 
1997) may mask any effects on ethanol consumption that would otherwise be 
detected.  
Further, the upregulation of NPY mRNA expression which occurred in the 
hypothalamus coincided with an enhancement in NPY protein levels in separate 
brain areas including the nucleus accumbens core and striatum of RIIβ -/- mice 
compared to wildtypes. This is not unexpected. In response to a stimulus or 
challenge, messenger RNA is transcribed from the DNA of genes and carries coding 
information to the ribosomes where protein synthesis can occur. Proteins then can 
remain in the cell body or be transported to the neuronal terminals. Therefore, 
changes in mRNA expression may be expected to occur in brain regions outside of 
those where protein differences can be detected. Importantly, dense populations of 
NPY synthesizing neurons are located in the arcuate nucleus of the hypothalamus 
and in the brainstem, specifically the locus coeruleus (Dagerlind & Schalling, 1988; 
Everitt et al., 1986). However, significant differences between RIIβ -/- and RIIβ +/+ in 
NPY mRNA were noted only in hypothalamic, but not brainstem, samples 
suggesting differences in the NPY-synthesizing populations. Interestingly, locus 
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coeruleus NPY neurons primarily project to multiple distinct nuclei of the 
hypothalamus while NPY-producing neurons in the arcuate nucleus are known to 
extend projections to other regions of the hypothalamus as well as to the nucleus 
accumbens and the central nucleus of the amygdala (Broberger, Johansen, 
Johansson, Schalling, & Hokfelt, 1998; Chronwall, 1985; Kask et al., 2002). Further, 
the aforementioned NPY neurocircuitries have been shown to be regulated by 
different mechanisms, specifically in response to stress or antidepressants (Makino, 
Baker, Smith, & Gold, 2000). Therefore, modifications of cAMP-PKA signaling 
induced by deletion of the RIIβ subunit of PKA may preferentially affect the arcuate-
accumbal NPY pathway resulting in the observed mRNA increases in the 
hypothalamus and protein enhancement in the NAc of RIIβ -/- mice. However, since 
we did not specifically isolate the LC region in our brainstem samples, it is possible 
that contributions from other areas of the brainstem washed out any expected 
differences in NPY mRNA in the brainstem. 
Historically, the majority of studies have investigated how NPY affects ethanol 
phenotypes while few have been concerned with the direct effect of ethanol on NPY 
levels. Therefore, the literature is limited and inconsistent. Interestingly, high or low 
dose, acute or repeated ethanol administration had no effect on NPY mRNA or 
protein levels in the hypothalamus in our studies. Consistent with our findings, 
ethanol injected daily for one week (0.8 g/kg) failed to alter the expression of NPY 
mRNA in the hypothalamus of Sprague-Dawley rats (Leibowitz et al., 2003). Further, 
both the high ethanol consuming inbred C57BL/6J mice and selectively bred P rats 
fail to exhibit a difference in hypothalamic NPY as compared to their respective low 
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alcohol drinking counterparts (Ehlers et al., 1998; Hayes, Knapp, Breese, & Thiele, 
2005) suggesting that ethanol exposure does not affect NPY signaling in this region. 
Conversely, one investigation of hypothalamic NPY mRNA following acute 
administration of ethanol in Sprague-Dawley rats shows that mRNA levels are 
decreased 4 hours post acute ethanol administration (Kinoshita et al., 2000). 
However, since mRNA is rapidly degraded, the 4-hour time point assessed in that 
study may miss peak changes and instead capture the degradation phase of the 
mRNA lifetime. 
Choosing the appropriate time point at which to measure mRNA and protein 
expression levels is crucial as mRNA is rapidly degraded with protein typically being 
only slightly more stable. In the studies discussed herein, mRNA expression was 
examined at 1 hour post-ethanol injection while protein levels were assessed 2 
hours following the final injection. Consistent with our choice of time point for mRNA 
expression, a temporal analysis of NPY mRNA expression induced by hypotensive 
hemorrhage showed peak increases in expression between 0.5 and 1 hour which 
remained elevated for up to 3 hours (Chan & Sawchenko, 1998). Further, 
suppression of NPY mRNA following restraint stress in rats was evident at 1 and 2 
hours post-stress manipulation but had begun to return to control levels by 4 hours 
after the stress treatment (Thorsell et al., 1998). Therefore, measuring mRNA four 
hours post ethanol injection, as was done by Kinoshita et al., misses the peak 
changes seen at 1 hour in other behavioral manipulations and is most likely 
capturing the degradation phase of the mRNA lifetime. As for protein levels, our 
study utilized a two hour time point for rapid sacrificing based on the protein 
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expression of c-fos, an immediate early gene, in response to ethanol administration 
since a temporal analysis of NPY protein expression has yet to be conducted. 
Immediate early genes are activated transiently and rapidly in response to stimuli, 
with other protein synthesis occurring thereafter. Temporal analysis of c-fos protein 
levels showed initial activation by 30 minutes with maximal activation noted at 120 
minutes following ethanol administration (K. M. Ogilvie et al., 1998) suggesting that a 
2-hour time point should be sufficient to witness the onset of NPY protein changes. 
However, additional research should include a more extensive temporal 
investigation of NPY mRNA and protein levels following ethanol injection.  
Interestingly, acute ethanol exposure in male RIIβ -/- and RIIβ +/+ mice 
decreased NPY immunoreactivity in the ventromedial and ventrolateral portions of 
the striatum while repeated ethanol injections had no effect on NPY-IR. The latter 
observation is consistent with reports that male Sprague-Dawley rats fail to exhibit 
any changes in NPY immunoreactivity in the striatum following a more rigorous, 
chronic exposure to ethanol. Specifically, rats given either 10 days of 12-hour 
exposure to ethanol vapor or exposed to 15 days of forced access to nutritionally 
complete ethanol diet show no significant effects of ethanol treatment when 
compared to non-ethanol-exposed rats (Roy & Pandey, 2002; Slawecki, Jimenez-
Vasquez, Mathe, & Ehlers, 2005). Further, no differences were observed in NPY 
levels in the caudate of Wistar rats, or selectively bred alcohol preferring (P) or non-
preferring (NP) rats following 7 weeks of 10-hour daily exposure to ethanol vapor 
(Ehlers et al., 1998). To the best of our knowledge, this is the first evidence 
suggesting an effect of acute ethanol exposure on NPY levels in the striatum.  
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Importantly, the nucleus accumbens and amygdala have been prominently 
implicated in reward, motivation, and the reinforcing effects of ethanol (DiChiara & 
Imperato, 1988; Koob et al., 1998). In fact, one theory of addiction suggests that 
alterations in NPY signaling in these regions play a critical role in the development of 
ethanol dependence (Koob, 2003; Koob & Le Moal, 2001). However, contrary to 
multiple indications, RIIβ -/- mice maintained on a C57BL/6J genetic background did 
not display changes in NPY levels compared to wildtypes in response to saline, 
acute ethanol, or repeated ethanol exposure in the nucleus accumbens or 
amygdala. This is in direct contradiction to reports which show that high ethanol 
consuming C57BL/6J mice exhibit reduced basal NPY signaling in the shell region of 
nucleus accumbens as well as multiple amygdaloid nuclei compared to low alcohol 
drinking mice (Hayes et al., 2005; Misra & Pandey, 2003). Further, acute ethanol 
administration (1.0 g/kg) in Sprague-Dawley rats was shown to increase NPY levels 
in the medial nucleus and basolateral amygdala as compared to saline control 
(Pandey, Ugale, Zhang, Tang, & Prakash, 2008). However, consistent with our 
findings, several studies of more extensive ethanol exposure indicate that ethanol 
exposure failed to induce changes in NPY signaling in the amygdala (Roy & Pandey, 
2002; Slawecki et al., 2005). Therefore, while factors contributing to the 
discrepancies are unclear, methodological differences such as precise ethanol dose, 
method of ethanol exposure, ethanol-sacrifice timing, or species differences are all 
possible explanations. 
As for sex effects in the experiments conducted herein, male and female mice 
were only utilized in the NPY mRNA study. Interestingly, a radioimmunoassay of 
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central NPY expression in rats indicated that male rats displayed higher NPY 
expression than females in the hippocampus, striatum, and hypothalamus (Rugarn, 
Hammar, Theodorsson, Theodorsson, & Stenfors, 1999). However, we report no 
differences in NPY mRNA levels between males and females in any condition or any 
analyzed brain region. While reasons for this discrepancy are not entirely clear, 
potential explanations for the differences could be explained by innate differences 
between species used, tissue extraction methodology, or assay parameters. Further, 
since sex did not affect NPY mRNA levels and since prior quintessential 
experiments which assessed NPY immunoreactivity in P/NP and HAD/LAD only 
utilized male rats (Ehlers et al., 1998; Hwang et al., 1999), we examined male mice 
only in the immunohistochemistry experiment.   
  In conclusion, this study provides the first direct evidence showing that 
mutant mice lacking the RIIβ subunit of PKA display increased NPY signaling in the 
hypothalamus, nucleus accumbens core, and striatum as compared to RIIβ +/+ 
mice. Interestingly, results from the hypothalamus of RIIβ -/- and RIIβ +/+ mice 
indicate that altered NPY production in this region may be responsible for alterations 
of feeding and/or energy homeostasis that are characteristic of RIIβ -/- mice. Future 
experiments will more precisely address this hypothesis. Further, RIIβ -/- mice are 
known to consume more ethanol than their wildtype controls but this increase is not 
associated with changes in NPY signaling in the nucleus accumbens shell or 
amygdala despite much evidence indicating that these regions are involved in the 
reinforcing properties of drugs of abuse and that NPY signaling in these regions 
contributes to ethanol consumption. Therefore, NPY signaling in these regions may 
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not play a role in the increased ethanol consumption characteristic of RIIβ -/- mice 
(Fee et al., 2004; Thiele et al., 2000b). Interestingly, the nucleus accumbens core 
and the striatum are known to be integrated with motor control areas of the brain 
(Carlson, 2007; Kelley, 1999; Nicola, Surmeier, & Malenka, 2000; Robinson & 
Berridge, 2000) allowing for the possibility that the heightened NPY signaling in 
these regions of RIIβ -/- mice may be involved in the locomotor stimulant properties 
of ethanol. Importantly, RIIβ -/- mice are more sensitive to the locomotor stimulating 
effects of ethanol than their wildtype littermate controls (Fee et al., 2006). Therefore, 
Chapter 3 will address the possibility that increased NPY in the nucleus accumbens 
core and/or striatum modulates ethanol-induced locomotor activity and/or ethanol-
induced behavioral sensitization. 
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Figure 2.1 Expression of NPY mRNA in the nucleus accumbens (A), hypothalamus 
(B), and brainstem (C) as determined by real-time RT-PCR. The data are expressed 
as the mean NPY copy number ± SEM per 10 ng cDNA sample based on a 
standard curve using Roche LightCycler software. * indicates a significant main 
effect of genotype (p<0.05). 
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Figure 2.2 NPY immunoreactivity in the nucleus accumbens (NAc). Representative 
photomicrographs are coronal brain slices (at approximately 1.0 mm anterior to 
bregma) taken from RIIβ +/+ (A) and RIIβ -/- (B) mice which received saline 
injections. Quantification of NPY immunoreactivity in the core (C) and shell (D) 
regions of the NAc were performed using Image J software and values are 
represented as mean density ± SEM.  * indicates a genotype difference (p < 0.05). 
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Figure 2.3 NPY immunoreactivity in the striatum. Representative photomicrographs 
are coronal brain slices (at approximately 1.0 mm anterior to bregma) taken from 
RIIβ +/+ (A) and RIIβ -/- (B) mice which received saline injections. Abbreviations: 
DM= dorsomedial; DL=dorsolateral; VM=ventromedial; VL=ventrolateral. 
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Figure 2.4 Quantification of NPY immunoreactivity in RIIβ -/- and RIIβ +/+ mice in 
each of the subregions of the striatum following saline, acute, or repeated ethanol 
injection was performed using Image J software and values are represented as 
mean density ± SEM.  
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Figure 2.5 Quantification of NPY immunoreactivity in RIIβ -/- and RIIβ +/+ mice in 
each of the subregions of the striatum was performed using Image J software and 
values are represented as mean density ± SEM. ** indicates a significant effect of 
genotype (p < 0.01) Abbreviations: DM= dorsomedial; DL=dorsolateral; 
VM=ventromedial; VL=ventrolateral. 
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Figure 2.6 Quantification of NPY immunoreactivity in the ventromedial (A) and 
ventrolateral (B) striatum following saline, acute ethanol, or repeated ethanol 
exposure was performed using Image J software and values are represented as 
mean density ± SEM. * indicates a significant difference between treatments (p < 
0.05). 
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CHAPTER 3 
 
NEUROPEPTIDE Y (NPY) IN THE NUCLEUS ACCUMBENS (NAc) CORE 
MODULATES ETHANOL-INDUCED LOCOMOTOR BEHAVIORS 
 
 
 
Introduction 
Previous reports from our laboratory have indicated that mice lacking normal 
production of the RIIβ subunit of PKA (RIIβ-/- mice) show enhanced sensitivity to the 
locomotor stimulant effects of ethanol as compared to wildtype littermate controls 
(Fee et al., 2006). Further, in the preceding chapter we showed that these RIIβ -/- 
mice display brain region specific enhancement of NPY immunoreactivity in the 
nucleus accumbens (NAc) core and striatum relative to RIIβ +/+ mice. Since it is 
known that the nucleus accumbens core and striatum are brain regions integrated in 
motor behavior (Carlson, 2007; Kelley, 1999; Nicola et al., 2000; Robinson & 
Berridge, 2000), it is possible that increased NPY in the NAc and/or striatum may be 
responsible for the enhanced ethanol-induced locomotor activity and/or ethanol-
induced behavioral sensitization observed in RIIβ -/- mice. 
NPY is a 36 amino acid neuromodulator with activity in a number of brain 
regions (Berglund et al., 2003; Colmer & Wahlestedt, 1993; Gray & Morley, 1986) 
which has been implicated in a wide range of biological functions including 
neurobiological responses to ethanol (Clark et al., 1984; Hansel et al., 2001; Heilig 
et al., 1993; Pandey et al., 2003a; Thiele & Badia-Elder, 2003; Woldbye et al., 1996). 
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There are currently 5 known receptor subtypes in the mouse: Y1, Y2, Y4, Y5, and Y6 
of which the Y1, Y2, and Y5 receptors are expressed centrally. The Y1 and Y5 
receptors are located postsynaptically with evidence suggesting primary roles in 
ethanol intake and feeding, respectively (Berglund et al., 2003; Thiele, Koh, & 
Pedrazzini, 2002). The Y2 receptor is primarily located presynaptically where it acts 
as an autoreceptor, inhibiting further release of NPY (Stanic et al., 2006). Studies 
performed in Y2 receptor deficient mice have also shown a role for this receptor in 
the modulation of voluntary ethanol consumption (Thiele, Naveilhan, & Ernfors, 
2004a; Thiele et al., 2004b). Therefore, it is imperative to investigate receptor 
subtype involvement as well as the overall role of NPY in ethanol-related behavior.  
Behavioral sensitization is defined as the long-lasting and progressive 
enhancement of the locomotor responses to repeated administration of a drug 
(Kalivas & Stewart, 1991). Specifically, repeated use of addictive drugs is thought to 
usurp the dopaminergic neural circuitry typically involved in reward and motivation 
causing progressive and persistent neuroadaptations. This circuitry includes 
dopaminergic projections within the ventral tegmental area, nucleus accumbens, 
amygdala, substantia nigra, and striatum (Pierce & Kalivas, 1997; Robinson & 
Berridge, 2003; White & Kalivas, 1998). Neuroadaptations in this circuitry are 
thought to underlie the increasingly hypersensitized behavioral response to the drug 
and are hypothesized to reflect an increased motivation to obtain the drug (Robinson 
& Berridge, 2000). Importantly, one theory of behavioral sensitization, proposed by 
Robinson and Berridge, asserts that craving for a drug sensitizes with repeated 
exposure to the drug (1993) and measures of locomotor sensitization may reflect 
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these increases in craving. The long-lasting changes in this pathway may explain 
why addicts crave drugs in general and why this drug craving persists even following 
a long-term abstinence period and in the face of strong negative outcomes. 
Therefore, understanding behavioral sensitization may provide insight into the 
mechanisms of addiction. 
In order to examine the effects of ethanol-induced locomotor activity and/or of 
ethanol-induced locomotor sensitization, a tool is needed which promotes chronic 
long-term manipulation of NPY signaling. Recombinant adeno-associated virus 
(rAAV) vectors are ideal candidates because they allow non-toxic gene expression 
in rodent brain that is functionally active over a period of up to one year (Haberman, 
McCown, & Samulski, 1998; Haberman et al., 2003; McCown et al., 1996). 
Moreover, when the coding sequence for the target protein is preceded by the 
secretory signal sequence for the laminar protein, fibronectin (FIB), the gene product 
is constitutively secreted by transduced cells (Haberman et al., 2003). Thus, by 
using a rAAV vector containing the secretion signal sequence for FIB and the coding 
sequence for NPY (rAAV-FIB-NPY) or a Y2 selective fragment of NPY (rAAV-FIB-
NPY13-36), one is able to transduce specific brain regions with a viral vector where 
subsequent gene expression leads to constitutive secretion of functionally active 
peptide over an extended period. 
In this investigation, we used both pharmacological and genetic procedures to 
evaluate the role of NPY and its receptors on ethanol-induced locomotor behaviors. 
We first utilized the rAAV-FIB-NPY vector to transduce neurons and constitutively 
secrete NPY in the NAc core or striatum of DBA/2J mice and then assess 
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subsequent ethanol-induced locomotor behaviors. Inbred DBA/2J mice were chosen 
because they are known to exhibit robust ethanol-induced locomotor sensitization 
(Lessov, Palmer, Quick, & Phillips, 2001; Phillips, Dickinson, & Burkhart-Kasch, 
1994). To further investigate the relationship between NPY and locomotor responses 
to ethanol, we explored the genetic contribution of NPY, and its receptors, to the 
development of ethanol-induced locomotor sensitization by examining mice lacking 
NPY (NPY -/-) or lacking the Y1 receptor of NPY (NPY Y1 -/-). Finally, we utilized 
transduction of the rAAV-FIB-NPY13-36 in the NAc core to evaluate the effects of 
blunting endogenous NPY release on ethanol-induced locomotor behaviors. 
Because RIIβ -/- mice exhibit enhanced ethanol-induced behavioral sensitization and 
increased levels of NPY in the NAc and striatum, here we directly determined if 
elevated NPY signaling in the ventral and dorsal striatum leads to enhanced ethanol-
induced locomotor activity and/or ethanol-induced behavioral sensitization. 
 
Methods 
 
Assessment of ethanol-induced locomotor activity or ethanol-induced 
behavioral sensitization in DBA/2J mice with increased synthesis and 
constitutive secretion of NPY in the NAc core or striatum 
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Animals 
Male DBA/2J mice (Jackson Laboratory, Bar Harbor, ME) were obtained at 6-
8 weeks of age and weighed between 18.3 and 26.5 grams at the beginning of the 
experiment. Mice were individually housed in polypropylene cages with corncob 
bedding (Teklad, Madison, WI) and were allowed ad libitum access to standard 
rodent chow (LabDiet, Brentwood, MO) and water. The colony room was maintained 
at 22ºC with a 12 hour:12 hour light:dark cycle. All procedures used in the present 
studies were conducted in compliance with the National Institute of Health guidelines 
and each protocol has been approved by the University of North Carolina 
Institutional Animal Care and Use Committee. 
 
Recombinant Adeno-Associated Viral Vector 
The AAV2 vectors were constructed as previously described (Haberman et 
al., 2003; McCown, 2006) within the University of North Carolina vector core.  
Briefly, the fibronectin signal sequence (FIB, nucleotides 208-303) was derived from 
the rat fibronectin mRNA sequence (Genbank accession # X15906) and 
oligonucleotides corresponding to both strands were generated (Midland Certified 
Reagent Company). AgeI overhangs were included such that the annealed 
oligonucleotides could be ligated in front of NPY in an AAV plasmid where gene 
expression is driven by the hybrid chicken-beta actin promoter. The NPY sequence 
was amplified by RT-PCR from rat brain RNA using primers directed to the mature 
peptide sequence such that melting and reannealing of 2 separate PCR products 
resulted in 5’AgeI and 3’ NotI overhangs (Zeng, 1998).  The 3’ primer contained a 
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stop codon to properly terminate translation. The PCR product was ligated into the 
AgeI-NotI resulting in plasmids pFIB-NPY.  The clone was sequenced to ensure 
accuracy. HEK 293 cells were transfected with the transgene plasmid, pACG2 and 
XX6-80 via calcium phosphate methods. Cells were lysed by freeze-thaw or 
deoxycholate, and cell lysates were centrifuged through a discontinuous iodixanol 
gradient. The virus was further purified over a Hi-trap heparin column (Amersham 
Pharmacia Biotech, Piscataway, NJ), dialyzed into phosphate-buffered saline and 
stored at -80°C until use. Recombinant virus titers were calculated by dot blot 
(Haberman et al., 1998). The AAV-FIB-NPY (3.3 x 1012 viral particles/ml) construct 
transduces neurons in vivo and constitutively secretes the gene product, NPY. 
Phosphate-buffered saline infusions were used as the control.  
 
Stereotaxic surgery 
Following 2 weeks of habituation, mice were anesthetized with a cocktail of 
ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and infused bilaterally with either 
rAAV-FIB-NPY (N=20) or Phosphate Buffered Saline (PBS)(N=19) via an injector 
designed to fit a 26 gauge cannula (Plastics One, Roanoke, VA). The injector was 
aimed at the core of the NAc and delivered 1 μl of fluid at a rate of 0.1 μl per minute 
via microsyringe attached to a Harvard Apparatus PHD 2000 microinfusion pump. 
The following coordinates were used: 1.4 mm anterior to bregma, ± 0.9 mm lateral to 
midline, and 4.7 mm ventral to skull surface. In the second study, we bilaterally 
infused 1.5 μl of rAAV-FIB-NPY (N=18) or PBS (N=18) into the striatum using the 
same rate parameters. The coordinates used were 0.8 mm anterior to bregma, ± 1.6 
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mm lateral to midline, and 2.5 mm ventral to skull surface. The infusion volumes and 
rates were chosen from pilot experiments to minimize fluid spread to other brain 
regions (See Figures 3.1 and 4.1). In each study, animals were monitored daily and 
allowed to recover for 2-weeks which ensured ample time for the transduction of the 
viral vector. 
 
RT-PCR Validation of Vector Activity In Vivo 
 See appendix 1 for description of this methodology.   
 
Ethanol-Induced Locomotor Activity and Ethanol-Induced Behavioral Sensitization 
All animals were transported to the locomotor testing room in their home 
cages during the light phase of their light:dark cycle and allowed to habituate for 30 
minutes prior to testing. A fan provided masking noise in the testing room.  For each 
locomotor activity trial, mice were removed from their homecages, given an 
intraperitoneal (i.p.) injection of ethanol or equivolume saline (all injections were 
given in a volume of 10 ml/kg) and placed into the center of an open-field arena that 
automatically recorded activity via photobeam breaks (Harvard Apparatus, Inc., 
Holliston, MA). The open field arena measured 40.64 cm by 40.64 cm by 30.48 cm 
and was made of clear Plexiglas. Corncob bedding was placed into the open field 
chamber to aid in cleaning and to prevent the buildup of odor. Testing sessions 
lasted 20 minutes.  
UEthanol-induced locomotor activity U: In order to allow for habituation to testing 
procedures and to establish a baseline locomotor activity, mice were given an i.p. 
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injection of saline on three separate trials (one every 2-3 days) and their activity 
levels were monitored. On subsequent trials, each animal received an i.p. injection 
of ethanol and was tested immediately following the injection for ethanol-induced 
locomotor activity over 11 trials, each conducted every 2-3 days. On trials 1-4, all 
mice received a 2.0 g/kg dose of ethanol (20% w/v ethanol in 0.9% NaCl) and 
animals received an injection of 1.5 g/kg ethanol (15% w/v ethanol in 0.9% NaCl) for 
the remaining trials. Data are presented as the change in locomotor activity from 
established saline baseline levels.  
UEthanol-induced behavioral sensitization U: For the experiment in which the 
vector was injected into the striatum, we utilized a slight modification to that 
described above. Briefly, baseline locomotor activity was monitored as described 
above. However, mice then received an i.p. injection of 1.5 g/kg ethanol (15% w/v 
ethanol in 0.9% NaCl) for 3 trials in order to establish an initial locomotor response 
to ethanol. Next, mice were exposed to 10 trials in which they received homecage 
injections of 2.5 g/kg ethanol (25% w/v ethanol in 0.9% NaCl). On the final test day, 
animals were once again given a 1.5 g/kg dose of ethanol (15% w/v ethanol in 0.9% 
NaCl) and placed in the locomotor arena. Activity data is presented as cm traveled in 
20 minutes while ethanol-induced locomotor sensitization was measured as ethanol 
test day activity minus the initial ethanol baseline activity.  
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Data Analyses 
All data are represented as mean ± standard error of the mean (SEM). Data 
were analyzed using analysis of variance (ANOVA), and t-tests were performed for 
planned comparisons. Significance was accepted at p<0.05 (two-tailed). 
 
Assessment of ethanol-induced locomotor activity and ethanol-induced 
behavioral sensitization in mutant mice lacking NPY or the NPY Y1 receptor 
 
Animals 
Male and female littermate NPY -/- and NPY +/+ mice on a 98% pure 
C57BL/6 background were used in the third study. These animals have been 
described previously (Erickson, Clegg, & Palmiter, 1996; Thiele et al., 2000a). Mice 
were 3-8 months old and weighed an average of 24.36 ± 0.47 grams at the start of 
experimentation with no significant difference between the genotypes [F(1,36) = 2.74; 
p = 0.107]. For the fourth experiment, we utilized male and female littermate NPY Y1 
-/- and NPY Y1 +/+ mice on a pure C57BL/6 background. These animals have been 
described elsewhere (Pedrazzini et al., 1998; Thiele et al., 2002). Mice were 3-6 
months old and weighed approximately 24.0 ± 0.55 grams at the start of the 
experiment with no significant difference between the genotypes [F(1,36) = 0.047; p = 
0.83]. 
As before, all mice were individually housed in polypropylene cages with 
corncob bedding (Teklad, Madison, WI) and were allowed ad libitum access to 
standard rodent chow (LabDiet, Brentwood, MO) and water. The colony room was 
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maintained at 22ºC with a 12 hour:12 hour light:dark cycle. All procedures used in 
the present studies were conducted in compliance with the National Institute of 
Health guidelines and each protocol has been approved by the University of North 
Carolina Institutional Animal Care and Use Committee. 
 
Assessment of Ethanol-Induced Locomotor Activity or Ethanol-Induced Behavioral 
Sensitization in NPY -/- Mice 
These procedures were similar to the previously mentioned paradigm with a 
few slight modifications. Briefly, all animals received 3 baseline saline injections 
(daily) followed by 5 i.p. injections of a 1.5 g/kg dose of ethanol (given every other 
day). Two weeks after the fifth injection, mice received 5 i.p. injections of a 2.0 g/kg 
dose of ethanol to establish an initial ethanol baseline prior to sensitization 
injections. Next, 10 homecage injections (2.5 g/kg ethanol) were given once daily. 
After homecage injections, mice were given test day ethanol injection (2.0 g/kg) or 
saline injection in a counterbalanced order on separate days with 3 days in between 
sessions. 
 
Assessment of Ethanol-Induced Locomotor Activity or Ethanol-Induced Behavioral 
Sensitization in NPY Y1 -/- Mice 
Baseline locomotor activity was established as mentioned above. Following 
baseline measures, animals received 3 i.p. injections of a 2.0 g/kg dose of ethanol 
(20% w/v), each followed by locomotor testing to determine an initial baseline 
response to ethanol. Next, mice received 10 i.p. injections of a 2.5 g/kg dose of 
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ethanol (25% w/v) in their homecages, once daily. On the test day, mice were again 
given an i.p. injection of a 2.0 g/kg dose of ethanol (20% w/v) to test for ethanol-
induced locomotor sensitization. To determine if changes in behavior were specific 
to ethanol injections, mice were given a final injection of saline and placed in the 
locomotor activity chambers to monitor activity levels. All injections were given 2-3 
days apart.  
 
Data Analyses 
All data are represented as mean ± standard error of the mean (SEM). Data 
were analyzed using analysis of variance (ANOVA) and t-tests were performed for 
planned comparisons. Significance was accepted at p<0.05 (two-tailed). 
 
Assessment of increased synthesis and constitutive secretion of a Y2 
receptor-selective fragment of NPY in the NAc core on ethanol-induced 
locomotor activity and sensitization 
 
Animals 
Male DBA/2J mice (Jackson Laboratory, Bar Harbor, ME) were obtained at 6-
8 weeks of age and weighed between 19.5 and 27.7 grams at the beginning of the 
experiment. Mice were individually housed in polypropylene cages with corncob 
bedding (Teklad, Madison, WI) and were allowed ad libitum access to standard 
rodent chow (LabDiet, Brentwood, MO) and water. The colony room was maintained 
at 22ºC with a 12 hour:12 hour light:dark cycle. All procedures used in the present 
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studies were conducted in compliance with the National Institute of Health guidelines 
and each protocol has been approved by the University of North Carolina 
Institutional Animal Care and Use Committee. 
 
Recombinant Adeno-Associated Viral Vector (rAAV-FIB-NPY13-36) 
 This virus was created in the same manner as mentioned above with the 
following exception: the rAAV-FIB-NPY13-36 vector contains the coding sequence for 
the Y2 fragment of NPY instead of the full length peptide (See (Foti, Haberman, 
Samulski, & McCown, 2007). Since the Y2 receptor is a presynaptic autoreceptor, 
this vector should effectively block the release of endogenous NPY in brain regions 
transduced by this vector. Further, for the experiment discussed herein, we have 
utilized a control viral vector containing the coding sequence for Green Flourescent 
Protein (GFP) preceded by the FIB sequence. Importantly, GFP is not endogenous 
to mammals and has no known neurobiological effects. Again, each clone was 
sequenced to ensure accuracy. AAV-FIB-NPY13-36 (3.3 X 1012 viral particles/ml) and 
AAV-FIB-GFP (4.2 x 1012 viral particles/ml) were produced as previously described 
(Haberman et al., 2003) within the UNC vector core. 
 
Stereotaxic surgery 
Following 2 weeks of habituation, mice were anesthetized with a cocktail of 
ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and infused bilaterally with either 
control virus (rAAV-FIB-GFP (N=19)) or rAAV-FIB-NPY13-36 (N=20) at a volume of 
0.5 μl per side at a rate of 0.1μl/min following the details described above. The 
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following coordinates were used: 1.4 mm anterior to bregma, ± 0.9 mm lateral to 
midline, and 4.7 mm ventral to skull surface. Animals were monitored daily and 
allowed to recover for 2-weeks which ensured ample time for the transduction of the 
viral vector. 
 
Ethanol-Induced Locomotor Sensitization 
Baseline locomotor activity was established as previously mentioned. 
Following baseline measures, animals received 3 intraperitoneal (i.p.) injections of a 
2.0 g/kg dose of ethanol (20% w/v in 0.9% NaCl) followed by locomotor activity 
monitoring to determine an initial response to ethanol. Mice then received 10 i.p. 
injections of a 2.5 g/kg dose of ethanol (25% w/v in 0.9% NaCl) in their homecages. 
Following the homecage injections, mice were again brought to the locomotor testing 
room, given an i.p. injection of a 2.0 g/kg dose of ethanol (20% w/v in 0.9% NaCl) 
and placed in the locomotor activity chamber to test for ethanol-induced locomotor 
sensitization. To determine if changes in behavior were specific to ethanol injections, 
mice were given a final injection of saline and placed in the locomotor activity 
chambers to monitor activity levels. All injections were given 2-3 days apart.  
 
Data Analyses 
All data are represented as mean ± standard error of the mean (SEM). Data 
were analyzed using analysis of variance (ANOVA) and t-tests were performed for 
post hoc analyses of planned comparisons. Significance was accepted at p<0.05 
(two-tailed). 
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Results 
 
Verification of Vector Transduction and Infusion Placement 
As previous work with the rAAV vectors involved rats (Haberman et al., 2003; 
McCown et al., 1996), it was important to confirm that these vectors would transduce 
neurons in the mouse brain, specifically the NAc. To this end, pilot studies were 
performed with a rAAV-GFP vector (which promotes expression, but not secretion, 
of GFP in transduced cells). As can be seen in Figure 3.1, GFP was expressed 
locally in the core of the NAc in rAAV-GFP treated mice when injected with 0.5 μl of 
virus. These observations confirm that our rAAV vectors transduced in cells of the 
core of the NAc of C57BL/6J mice. Further, the duration of vector activity in vivo was 
validated by demonstrating the presence of appropriate vector-derived mRNA in 
microdissected nucleus accumbens or striatal tissue of DBA/2J mice infused with 
rAAV-FIB-NPY (Figures A.1 and A.3) or rAVV-FIB-NPY13-36 (Figure A.4). Please see 
appendix 1 for details. 
 
DBA/2J mice infused with rAAV-FIB-NPY in the NAc core displayed enhanced 
ethanol-induced locomotor activity compared to PBS-infused mice 
Locomotor activity data from DBA/2J mice infused with either PBS or rAAV-
FIB-NPY in the NAc core are presented in Figure 3.2. A two-way (days x viral 
treatment) repeated-measures ANOVA performed on locomotor activity across 
saline and all 11 ethanol trials revealed a main effect of days [F(1,11) = 43.23; p < 
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0.001] indicating differential locomotor responses in DBA/2J mice following a dose of 
saline, 1.5 g/kg, or 2.0 g/kg ethanol. Specifically, when injected with a moderate 2.0 
g/kg dose of ethanol (injections 1-4), all mice showed a reduction in average 
ethanol-induced locomotor activity compared to saline baseline which is indicative of 
high sensitivity to the sedative properties of ethanol. Further, when injected with a 
low 1.5 g/kg dose of ethanol (injections 5-11), all mice displayed an increased 
locomotor activity over saline baseline levels indicating an enhanced sensitivity to 
the locomotor stimulant effects of ethanol. However, there was no significant effect 
of treatment [F(1,37) = 1.30; p = 0.262] or of the days x viral treatment interaction 
[F(1,11) = 1.26; p = 0.245] (Figure 3.2A). Interestingly, when data were expressed as a 
change from baseline saline activity as an indicator of ethanol-induced locomotor 
activity (Figure 3.2B), a two-way (days x viral treatment) repeated-measures ANOVA 
revealed a significant effect of days [F(1,10) = 44.32; p < 0.001] and of viral treatment 
[F(1,37) = 5.41; p = 0.026] but not of the days x treatment interaction [F(1,10) = 1.01; p < 
0.431]. Post hoc tests performed on the viral treatment main effect indicated that 
animals which received an infusion of rAAV-FIB-NPY exhibited an enhancement of 
ethanol-induced locomotor activity as compared to PBS infused mice on trials 1, 7, 
and 10 suggesting that mice with elevated levels of NPY in the NAc (the rAAV-FIB-
NPY group) are more sensitive to the locomotor stimulant properties of ethanol as 
compared to control-treated mice.  
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DBA/2J mice infused with rAAV-FIB-NPY in the striatum exhibited reduced ethanol-
induced locomotor sensitization compared to those infused with PBS during the first 
5 minutes of locomotor activity assessment 
Figure 3.3A shows the total 20-minute locomotor activity response of DBA/2J 
mice infused with either PBS or rAAV-FIB-NPY in the striatum following i.p. injection 
of saline and ethanol. A two-way (days x viral treatment) repeated-measures 
ANOVA performed on locomotor activity data failed to reveal a significant main effect 
of days [F(2,50) = 1.60; p = 0.212], viral treatment [F(1,25) = 0.005; p = 0.946], or days x 
viral treatment interaction [F(1,50) = 2.94; p = 0.062]. However, paired sample t-tests 
performed as planned comparisons indicate that PBS-treated mice exhibit ethanol-
induced sensitization, as measured by significantly increased locomotor activity in 
response to ethanol injection on the ethanol test day as compared to initial ethanol 
(p = 0.018), while mice infused with rAAV-FIB-NPY failed to exhibit this ethanol-
induced sensitization (p = 0.492). Similarly, when ethanol test day locomotor activity 
data (20 min) were expressed as change from saline baseline levels (Figure 3.3B), a 
one-way ANOVA revealed that viral treatment did not have any effect on ethanol-
induced locomotor activity [F(1,25) = 2.44; p = 0.131]. Further, when data were 
expressed as the change in locomotor activity relative to the first ethanol injection, 
the assessment of ethanol-induced behavioral sensitization, a one-way ANOVA 
revealed no significant difference between rAAV-FIB-NPY- and control-treated mice 
on measures of ethanol-induced locomotor sensitization [F(1,25) = 3.77; p = 0.063] 
(Figure 3.3C).      
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Locomotor activity measures were collected in 4 bins of 5 minutes each which 
are generally presented as total 20-minute activity. However, it has been suggested 
that the optimal test-trial duration for sensitization to ethanol in DBA/2J mice is 5 
minutes (Cunningham, Niehus, Malott, & Prather, 1992). Therefore, figure 3.4 shows 
the locomotor activity responses of DBA/2J mice infused with rAAV-FIB-NPY or PBS 
into the striatum during the first 5 minutes in the locomotor monitoring chamber. 
Figure 3.4A shows the raw 5-minute locomotor activity response of DBA/2J mice 
infused with either PBS or rAAV-FIB-NPY in the striatum following i.p. injection of 
saline and ethanol. A two-way (days x viral treatment) repeated-measures ANOVA 
performed on 5-minute locomotor activity data reveal a significant main effect of 
days [F(2,50) = 45.10; p < 0.001] and days x viral treatment interaction [F(2,50) = 4.27; p 
= 0.019], but not of treatment [F(1,25) = 0.20; p = 0.658]. Post hoc analysis of the days 
x treatment interaction failed to reveal a significant difference between rAAV-FIB-
NPY-infused and PBS-infused mice on any individual trial. Further, paired sample t-
tests performed as planned comparisons indicate that mice with striatal infusion of 
PBS or rAAV-FIB-NPY exhibit ethanol-induced sensitization, as measured by 
significantly increased locomotor activity in response to ethanol injection on the 
ethanol test day as compared to initial ethanol (p <0.001 and p = 0.017, 
respectively). When ethanol test day locomotor activity data (5 min) were expressed 
as change from saline baseline levels (Figure 3.4B), a one-way ANOVA revealed 
that viral treatment did not have any effect on ethanol-induced locomotor activity 
[F(1,25) = 2.18; p = 0.152]. Interestingly, when data were expressed as the change in 
locomotor activity relative to the first ethanol injection, the assessment of ethanol-
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induced behavioral sensitization, one-way ANOVA revealed that rAAV-FIB-NPY 
infusion in the striatum reduced ethanol-induced locomotor sensitization as 
compared to PBS-infused mice [F(1,25) = 6.41; p = 0.018] (Figure 3.4C). Therefore, 
chronic NPY secretion in the striatum of DBA/2J mice was protective against 
ethanol-induced locomotor sensitization during a 5-minute testing procedure.      
 
NPY -/- mice exhibited reduced ethanol-induced locomotor activity and ethanol-
induced locomotor sensitization compared to NPY +/+ mice  
The locomotor responses of NPY -/- and NPY +/+ mice following saline or 
ethanol injection can be seen in Figure 3.5A. A three-way (days x genotype x sex) 
repeated-measures ANOVA revealed a main effect of days [F(4,136) = 14.76; p < 
0.001] and sex [F(1,34) = 4.71; p = 0.037] and significant interaction effects of days x 
genotype [F(4,136) = 5.68; p < 0.001] and days x sex [F(4,136) = 2.90; p = 0.024]. The 
observed main effect of sex revealed that female mice exhibited increased 
locomotor activity as compared to males (Figure 3.5B). Further, post hoc analysis of 
the days x genotype interaction revealed that NPY -/- mice were less active than 
wildtype mice on the ethanol test day [F(1,36) = 6.96; p = 0.012] (Figure 3.5A) while a 
similar analysis of the days x sex interaction revealed a significant increase in 
female locomotor activity in response to a 2.0 g/kg dose of ethanol [F(1,36) = 8.47; p = 
0.006] and on ethanol test day [F(1,36) = 5.35; p = 0.027] (Figure 3.5B). However, 
there were no significant main effects of genotype [F(1,34) = 2.47; p = 0.125], 
genotype x sex [F(1,34) = 1.91; p = 0.176], or days x genotype x sex [F(4,136) = 1.34; p 
= 0.258]. Paired sample t-tests performed as planned comparisons indicated that 
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both NPY -/- and NPY +/+ mice exhibited ethanol-induced sensitization (p = 0.011 
and p < 0.001, respectively), as measured by a significant increase in ethanol test 
day activity relative to activity levels in response to baseline ethanol injection (2.0 
g/kg). However, NPY -/- mice showed blunted sensitization compared to NPY 
wildtype mice.  
Figure 3.6A depicts ethanol-induced locomotor activity in NPY -/- and NPY 
+/+ mice defined as the change in activity on ethanol test day relative to baseline 
levels of activity following saline injections. The change in activity between initial and 
final saline injections is presented for comparison. A three-way (days x sex x 
genotype) repeated-measures ANOVA reveals a significant effect of days [F(1,34) = 
30.87; p < 0.001] suggesting that enhanced locomotor activity was specific to 
ethanol administration. Further, analysis revealed a significant days x genotype 
interaction [F(1,34) = 14.02; p = 0.001]. Post hoc analysis of this interaction revealed 
that NPY -/- mice displayed reduced activity following test day ethanol administration 
as compared to NPY +/+  [F(1,36) = 4.65; p = 0.038] but there was no difference 
between the genotypes following saline administration [F(1,36) = 2.20; p = 0.147] 
indicating that NPY -/- mice are less sensitive to the locomotor stimulant properties 
of ethanol. Statistical analysis of the sex variable did not reveal any significant main 
effects or interactions on measures of ethanol-induced locomotor activity.    
Figure 3.6B shows the ethanol-induced behavioral sensitization as defined by 
a change in activity from initial ethanol (2.0 g/kg) to test day. A three-way (days x 
sex x genotype) revealed a significant effect of days [F(1,34) = 30.87; p < 0.001] and 
of the days x genotype interaction [F(1,34) = 14.02; p = 0.001]. Once again, analysis of 
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the sex variable did not reveal any significant effects or interactions. Post hoc 
analysis confirmed that NPY -/- mice displayed a significant attenuation of ethanol-
induced locomotor sensitization [F(1,36) = 8.75; p = 0.005] and exhibited less saline-
induced decreases in locomotor activity compared to NPY +/+ mice [F(1,34) = 4.60; p 
= 0.039].  
 
NPY Y1 -/- mice showed increased ethanol-induced locomotor sensitization 
compared to NPY Y1 +/+ mice 
Locomotor responses of NPY Y1 -/- and NPY Y1 +/+ mice following saline or 
ethanol injection are shown in Figure 3.7A. A three-way (days x sex x genotype) 
repeated-measures ANOVA revealed a main effect of days [F(3,96) = 42.39; p < 
0.001], genotype [F(1,32) = 18.65; p < 0.001], and days x genotype interaction [F(3,96) = 
3.25; p = 0.025]. In this analysis, sex was included as a variable of interest but failed 
to reveal significant effects or interactions. Analyses indicated that NPY Y1 -/- mice 
were more active than NPY Y1 +/+ mice. Consistently, post hoc tests of the days x 
genotype interaction revealed a significant difference in locomotor activity between 
NPY Y1 -/- and NPY Y1 +/+ mice on the initial saline [F(1,34) = 12.22; p = 0.001], 
ethanol test day [F(1,34) = 12.10; p = 0.001], and final saline days [F(1,34) = 8.12; p = 
0.007]. Paired sample t-tests of performed as planned comparisons revealed that 
both NPY Y1 -/- and NPY Y1 +/+ mice experienced enhanced locomotor activity on 
the ethanol test day when compared to initial ethanol responses (p < 0.001 for both). 
Figure 3.7B depicts ethanol-induced locomotor activity in NPY Y1 -/- and NPY 
Y1 +/+ mice defined as the change in activity on the ethanol test day relative to 
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baseline activity following saline injections. The change in activity between initial and 
final saline injections is presented for comparison. A three-way (days x sex x 
genotype) repeated-measures ANOVA reveals a significant effect of days [F(1,32) = 
56.74; p < 0.001] indicating that enhanced locomotor activity was specific to ethanol 
administration. However, there were no other significant main or interaction effects 
of any variable analyzed.   
Figure 3.7C shows the ethanol-induced behavioral sensitization as defined by 
a change in activity from initial ethanol (2.0 g/kg) to test day in NPY Y1 -/- and NPY 
Y1 +/+ mice. A three-way (days x sex x genotype) repeated-measures ANOVA 
revealed a significant effect of days [F(1,32) = 56.74; p < 0.001] and of genotype 
[F(1,32) = 5.04; p = 0.032]. Enhanced locomotor activity following repeated injections 
was specific to ethanol. Further, post hoc analysis revealed that NPY Y1 -/- mice 
displayed significantly greater ethanol-induced locomotor sensitization [F(1,34) = 6.75; 
p = 0.014] but did not differ from wildtype mice in response to saline injections [F(1,34) 
= 0.73; p = 0.401].  
 
DBA/2J mice infused with rAAV-FIB-NPY13-36 in the NAc core display attenuated 10- 
minute ethanol-induced locomotor activity as compared to DBA/2J mice infused with 
rAAV-FIB-GFP  
Figure 3.8A shows the total 20-min locomotor responses of DBA/2J mice 
infused with either rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the NAc core. A two-way 
(days x viral treatment) repeated-measures ANOVA revealed a significant effect of 
days [F(3,102) = 24.90; p < 0.001]. However, there was not a significant effect of viral 
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treatment [F(1,34) = 0.65; p = 0.427] or a days x treatment interaction effect [F(3,102) = 
1.36; p = 0.259]. Paired sample t-tests performed as planned comparisons revealed 
that all animals displayed an increase in locomotor activity following test day ethanol 
administration compared to initial ethanol injection (rAAV-FIB-GFP, p = 0.002; rAAV-
FIB-NPY13-36, p = .016).  
Figure 3.8B depicts ethanol-induced locomotor activity in DBA/2J mice 
transfected with rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the NAc core defined as the 
change in activity on the ethanol test day relative to baseline activity following saline 
injections. The change in activity between initial and final saline injections is 
presented for comparison. A two-way (days x viral treatment) repeated-measures 
ANOVA reveals a significant effect of days [F(1,34) = 66.07; p < 0.001] showing that 
enhanced locomotor activity was specific to ethanol administration. However, there 
were no significant main or interaction effects of any other variable analyzed.   
Figure 3.8C shows the ethanol-induced behavioral sensitization as defined by 
a change in activity from initial ethanol (2.0 g/kg) to test day in DBA/2J mice 
transfected with rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the NAc core. A two-way 
(days x viral treatment) repeated-measures ANOVA revealed a significant effect of 
days [F(1,34) = 66.07; p < 0.001] but not of viral treatment or viral treatment x days 
interaction. Therefore, enhanced locomotor activity following repeated injections was 
specific to ethanol administration but transduction of rAAV-FIB-NPY13-36 in the NAc 
did not affect ethanol-induced behavioral sensitization compared to control-treated m 
ice.  
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However, since various studies have indicated differential locomotor 
responses following experimental manipulation at 10 minutes of activity monitoring 
(Aragon, Trudeau, & Amit, 1992; Miquel, Correa, Sanchis-Segura, & Aragon, 1999; 
Weathersby, Becker, & Hale, 1994), figure 3.9A shows the 10-min locomotor 
responses of DBA/2J mice infused with either rAAV-FIB-GFP or rAAV-FIB-NPY13-36 
in the NAc core. A two-way (days x viral treatment) repeated-measures ANOVA 
revealed a significant effect of days [F(3,102) = 38.24; p < 0.001] and of the days x 
treatment interaction [F(3,102) = 3.09; p = 0.031]. However, there was not a significant 
effect of viral treatment [F(1,34) = 1.48; p = 0.233]. Post hoc analysis of the days x 
treatment interaction revealed that mice infused into the NAc core with rAAV-FIB-
NPY13-36 were less active on the ethanol test day as compared to the control virus-
infused mice. Further, paired sample t-tests performed as planned comparisons 
revealed that all animals displayed an increase in locomotor activity following test 
day ethanol administration compared to initial ethanol injection (rAAV-FIB-GFP, p < 
0.001; rAAV-FIB-NPY13-36, p = 0.005).  
Figure 3.9B depicts 10-minute ethanol-induced locomotor activity in DBA/2J 
mice transfected with rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the NAc core defined 
as the change in activity on the ethanol test day relative to baseline activity following 
saline injections. The change in activity between the initial and final saline injections 
is presented for comparison. A two-way (days x viral treatment) repeated-measures 
ANOVA revealed a significant effect of days [F(1,34) = 77.61; p < 0.001] suggesting 
that enhanced locomotor activity was specific to ethanol administration. Further, 
analysis revealed a days x viral treatment interaction effect [F(1,34) = 5.22; p = 0.029] 
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with post hoc analysis revealing that mice treated with rAAV-FIB-NPY13-36 in the NAc 
core displayed reduced ethanol-induced locomotor activity compared to rAAV-FIB-
GFP mice. However, there was no significant effect of viral treatment [F(1,34) = 2.12; 
p = 0.154].   
Figure 3.9C shows the ethanol-induced behavioral sensitization as defined by 
a change in activity from initial ethanol (2.0 g/kg) to test day in DBA/2J mice 
transfected with rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the NAc core. A two-way 
(days x viral treatment) repeated-measures ANOVA revealed a significant effect of 
days [F(1,34) = 77.61; p < 0.001] and days x treatment interaction [F(1,34) = 5.22; p = 
0.029] but not of viral treatment [F(1,34) = 0.92; p = 0.344]. Post hoc analysis of the 
interaction failed to reveal a difference between mice infused with rAAV-FIB-GFP or 
rAAV-FIB-NPY13-36 in the NAc core on measures of ethanol-induced behavioral 
sensitization. Therefore, the enhancement of locomotor responses following 
repeated injection was specific to ethanol but rAAV-FIB-NPY13-36 in the NAc did not 
affect ethanol-induced behavioral sensitization as compared to control-treated mice.  
 
Discussion 
 
In this investigation we have shown that NPY signaling, specifically within the 
nucleus accumbens core and the striatum, plays a role in ethanol-induced locomotor 
behaviors. We reported that DBA/2J mice infused with a viral vector, which 
constitutively secretes NPY from transduced neurons in the core region of the 
nucleus accumbens displayed enhanced ethanol-induced locomotor activity. 
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Consistently, mice infused with a vector which blunts endogenous NPY signaling in 
the core region of the NAc (rAAV-FIB-NPY13-36) exhibited attenuated ethanol-
induced locomotor activity relative to control-infused mice. However, striatal infusion 
of rAAV-FIB-NPY reduced ethanol-induced locomotor sensitization during the first 5 
minutes of the locomotor trials. Further, mice lacking NPY (NPY -/- mice) exhibited 
reduced ethanol-induced locomotor behavior and ethanol-induced behavioral 
sensitization while NPY Y1 -/- mice displayed an enhanced ethanol-induced 
sensitization relative to respective wildtype controls. To our knowledge, these are 
the first reports indicating a direct role for NPY signaling in modulating ethanol-
induced locomotor activity and/or ethanol-induced locomotor sensitization. 
The core of the nucleus acccumbens and the striatum were chosen as 
candidate regions to investigate the role of NPY in ethanol-induced locomotor 
behaviors based on previous findings. In chapter 2, we reported that RIIβ -/- mice, 
which show enhanced ethanol-induced locomotor activity and ethanol-induced 
locomotor sensitization (Fee et al., 2006), display higher levels of NPY in the 
nucleus accumbens core and the striatum compared to wildtype controls. Further, 
multiple studies have indicated a role for these structures in the expression of motor 
behaviors (Herrero, Barcia, & Navarro, 2002; Kelley, 1999; Nicola et al., 2000; 
Zahm, 1999; Zahm, 2000). Specifically, the development of psychomotor stimulant 
locomotor sensitization is known to be associated with structural plasticity within the 
basal ganglia (Hamlin, McNally, Westbrook, & Osborne, 2009; Li, Acerbo, & 
Robinson, 2004).  
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In the NAc core, viral vector-induced constitutive secretion of NPY promoted 
enhanced locomotor activity following repeated ethanol injections in inbred DBA/2J 
mice. Consistently, NAc core infusion of the viral vector thought to blunt endogenous 
NPY signaling (rAAV-FIB-NPY13-36) attenuated ethanol-induced locomotor activity. 
On the other hand, intra-striatum infusion of the rAAV-FIB-NPY in DBA/2J mice 
protected against ethanol-induced locomotor sensitization. Therefore, we suggest 
that NPY signaling can exert opposing effects on ethanol-induced locomotor 
behaviors, and that these effects are brain-region dependent.   
Although the striatum and nucleus accumbens core display similar 
histological and neurochemical characteristics and are both known to be involved in 
motor behavior, an important observation is that efferent innervation and afferent 
projection areas differ between these structures (Groenewegen, 2003; Smith & 
Bolam, 1990). Specifically, the striatum receives glutamatergic afferents from the 
thalamus and cortex as well as dopaminergic projections from the substantia nigra 
pars compacta (Graybiel, 2005). The medium spiny neurons in the striatum then 
project to two primary regions, the globus pallidus and the ventral substantia nigra 
pars reticulata (Herrero et al., 2002). Conversely, the core of the nucleus accumbens 
receives afferent projections from the lateral entorhinal cortex, basal amygdaloid 
complex, thalamus, and ventral pallidum, while efferent neurons project to the dorsal 
regions of the ventral pallidum and to the dorsomedial substantia nigra pars 
reticulata (Groenewegen, Wright, Beijer, & Voorn, 1999; Voorn, Vanderschuren, 
Groenewegen, Robbins, & Pennartz, 2004). Therefore, neurobiological contributions 
arising from differential afferent and efferent projections may contribute to the 
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opposing effects on ethanol-induced locomotor behaviors following chronic secretion 
of NPY observed in the striatum and nucleus accumbens core.   
An interesting theory is that NPY may modulate ethanol-induced locomotor 
behaviors via interactions with other neurotransmitter systems within the core of the 
nucleus accumbens or striatum. Likely candidates include the dopamine and/or 
glutamate systems. Dopaminergic activity in nigrostriatal neurons is known to be 
involved in the initiation of movement (Gerfen & Engber, 1992; Gerfen et al., 1990). 
Further, behaviors mediated by the striatum and nucleus accumbens, including 
motor planning and drug seeking, have been shown to depend on intact dopamine 
innervation (Nicola et al., 2000). Extensive literature also suggests that sensitization 
to a variety of drugs of abuse leads to an increase in dopaminergic 
neurotransmission in the striatum and in the core region of the nucleus accumbens 
(Cadoni & Di Chiara, 1999; Cadoni & Di Chiara, 2000; Cadoni, Solinas, & Di Chiara, 
2000). Of note, striato-pallidal neurons are known to express dopamine D2 
receptors, which are thought to be responsible for movement inhibition, while the 
striatonigral neurons express dopamine D1 receptors and facilitate movement (Ade, 
Janssen, Ortinski, & Vicini, 2008; Gerfen et al., 1990). However, while 
accumbonigral projections express D1 receptors, both D1 and D2 receptors are 
expressed in the projections from the nucleus accumbens to the ventral pallidum 
(Robertson & Jian, 1995). These receptor distribution differences may allow for 
specific receptor-mediated behavioral responses to ethanol, which could explain the 
opposing results observed in the NAc core in comparison to the striatum.  
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Interestingly, previous literature has proposed a relationship between the 
dopamine and NPY systems, including proposed reciprocal regulatory activity 
between the systems (Heilig & Widerlov, 1990; Josselyn & Beninger, 1993; 
Kerkerian, Salin, & Nieoullon, 1988; Midgley et al., 1994). Specifically, dopamine has 
been shown to stimulate NPY gene expression, while lesions of nigrostriatal 
dopaminergic neurons led to a decrease in NPY immunoreactivity in the NAc core 
(Lindefors, Brene, Herrera-Marschitz, & Persson, 1990; Salin, Kerkerian, & 
Nieoullon, 1990). Importantly, in vitro data suggests that NPY administration was 
able to enhance dopamine release in the nucleus accumbens and striatum of rats 
(Ault, Radeff, & Werling, 1998; Ault & Werling, 1997). Therefore, NPY may modulate 
ethanol-induced locomotor behaviors via an interaction with dopaminergic pathways.  
Glutamate signaling has also been implicated in locomotor behaviors (Cauli, 
Mlili, Llansola, & Felipo, 2007). Specifically, sensitization to psychostimulants is 
linked to an increase in glutamate release and neurotransmission in the NAc core 
and striatal regions and to a redistribution of glutamate receptors in the nucleus 
accumbens (Ghasemzadeh, Mueller, & Vasudevan, 2009; Kerkerian-Le Goff et al., 
1992; Pierce, Bell, Duffy, & Kalivas, 1996; Trujillo & Akil, 1995). Further, concurrent 
peripheral administration of glutamate receptor antagonists with cocaine prevented 
the development of psychomotor sensitization (Li et al., 1999). Interestingly, 
extracellular glutamate levels are regulated and maintained by the homer family of 
proteins via interactions with metabotropic glutamate receptors in the post-synpaptic 
density and these proteins are thought to be candidate regulators of ethanol-induced 
plasticity (Szumlinski, Ary, & Lominac, 2008a; Szumlinski, Ary, Lominac, Klugmann, 
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& Kippin, 2008b). Importantly, Homer2 -/- mice exhibit reduced basal extracellular 
glutamate in the nucleus accumbens and these mice failed to exhibit ethanol-
induced sensitization following repeated ethanol exposure (Kalivas, Szumlinski, & 
Worley, 2004; Szumlinski et al., 2005). Moreover, viral vector overexpression of 
Homer2 in the NAc facilitated the development of sensitization to the locomotor 
stimulant effects of a moderate dose of ethanol (Szumlinski et al., 2008b). Taken 
together, the upregulation of NPY signaling in the present work may potentiate 
glutamate activity in the nucleus accumbens core, a mechanism that may 
subsequently lead to enhanced ethanol-induced locomotor activity and behavioral 
sensitization. On the other hand, downregulation or elimination of NPY signaling 
may be associated with blunted glutamate activity in the NAc core, which may 
account for attenuated ethanol-induced locomotor activity in NPY -/- mice and in 
mice treated with the rAAV-FIB-NPY13-36 vector. Since a majority of the available 
literature addressed the relationship between glutamate and NPY in the core of the 
NAc, future research should examine the potential relationship between these 
systems in the striatum. Moreover, future research is required to directly assess 
possible glutamate/NPY interactions in the NAc core and striatum in the 
development of ethanol-induced behavioral sensitization. 
A second major finding in these experiments involves genetically modified 
mice. Specifically, mice lacking NPY are less sensitive to the locomotor stimulant 
properties of ethanol and display reduced ethanol-induced behavioral sensitization 
compared to wildtype mice. Further, we reported a significant effect of sex on 
locomotor activity such that NPY -/- and NPY +/+ females were more active than 
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respective males. This finding is consistent with recent literature characterizing the 
behavioral profile of a new mouse model of NPY deficiency, in which female mice 
also displayed increased open-field locomotor activity relative to male mice (Karl, 
Duffy, & Herzog, 2008). However, the sex differences were absent from measures of 
ethanol-induced locomotor sensitization, suggesting that the development of 
ethanol-induced sensitization is not sex-dependent. Conversely, mice lacking the Y1 
receptor of NPY displayed enhanced ethanol-induced locomotor sensitization and an 
overall increase in locomotor activity compared to wildtype mice. The latter finding is 
directly opposed to the original behavioral characterization of these mice which 
indicated that NPY Y1 -/- mice were less active than wildtype mice (Pedrazzini et al., 
1998) and others showing no genotype difference in locomotor activity (Costoli et al., 
2005). Interestingly, all animals used in the aforementioned studies were obtained 
from the same original population and maintained on a C57BL/6J genetic 
background. However, consistent with our results, a study of locomotor activity 
performed in Y1 -/- mice maintained on a mixed C57BL/6 x 129SvJ genetic 
background showed that NPY Y1 -/- mice displayed increased locomotor activity 
relative to wildtype mice (Karl, Burne, & Herzog, 2006). While the reasons for these 
inconsistencies are unclear, methodological differences, unknown environmental 
factors, as well as differences in genetic background may have contributed to the 
discrepancies.  
Importantly, since NPY -/- mice displayed reduced ethanol-induced locomotor 
behaviors, results are consistent with those obtained following viral vector infusion in 
the NAc suggesting that NPY signaling potentiates ethanol-induced locomotor 
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activity and behavioral sensitization However, NPY Y1 -/- mice displayed an 
enhanced ethanol-induced locomotor sensitization as compared the respective 
wildtype controls. The NPY Y1 receptor has previously been implicated in 
neurobiological responses to ethanol. Specifically, NPY Y1 -/- mice are known to 
consume higher amounts of ethanol than their wildtype controls while central or 
peripheral administration of a Y1 antagonist suppressed ethanol consumption in 
C57BL/6J mice (Sparta et al., 2004; Thiele et al., 2002). Further, male NPY Y1 -/- 
mice are less sensitive to a sedative dose of ethanol than NPY Y1 +/+ mice (Thiele 
et al., 2002). However, because this is the first evidence implicating the NPY Y1 
receptor in ethanol-induced locomotor behaviors, future research needs to more 
thoroughly explore the function of NPY Y1 in the underlying molecular, cellular, and 
neurobiological correlates of this phenomenon.   
The results of the knockout experiments presented herein clearly implicate 
NPY and the NPY Y1 receptor in ethanol-induced locomotor behaviors, although the 
reason for the opposing effects in the different genetic knockouts remains unclear. 
However, it is likely that compensatory changes in the receptor expression levels of 
other NPY receptor subtypes in the NPY Y1 -/- mice may contribute to the noted 
differences between experiments. Specifically, experiments have revealed that 
deletion of the Y1 receptor leads to brain-region specific changes in Y2 and, to a 
lesser extent, Y5 receptor expression (Wittmann, Loacker, Kapeller, Herzog, & 
Schwarzer, 2005). While further experimentation is needed, the results from the 
genetic knockout experiments suggest that NPY signaling, and specifically the NPY 
Y1 receptor, are involved in the modulation of ethanol-induced locomotor behaviors.        
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In conclusion, we demonstrate that NPY signaling in the nucleus accumbens 
core and striatum modulate ethanol-induced locomotor activity and ethanol-induced 
behavioral sensitization. Much work still needs to be done in order to determine the 
exact mechanisms of this phenomenon. However, it raises the interesting possibility 
that pharmacological manipulations aimed at NPY signaling mechanisms could be 
potential therapeutic agents in the treatment of addiction.   
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Figure 3.1 Photomicrographs of 50 μm coronal slices cut through the core region of 
the nucleus accumbens (NAc) of C57BL/6J mice given site-directed infusion of a 
rAAV-GFP vector aimed at the NAc core (0.5 μl). Ten days after infusion mice were 
perfused and their brains removed. Slices display strong expression of GFP in cell 
bodies and terminals, a finding that verifies that the rAAV vector is transduced into 
the NAc core of C57BL/6J mice. Images were photographed using 10x and 20x 
objectives. 
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Figure 3.2 Raw locomotor activity during a 20-minute session in DBA/2J mice 
infused with either PBS or rAAV-FIB-NPY in the NAc core following saline and 
ethanol administration (A). B represents locomotor activity corrected for basal 
activity as an indicator of ethanol-induced locomotor activity. The saline baseline is 
an average of the locomotor activity following three separate habituation trials. 
Values are represented as mean ± SEM. * indicates a significant effect of vector 
treatment (p < 0.05). 
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Figure 3.3 Raw locomotor activity during a 20-minute session in DBA/2J mice 
infused with either PBS or rAAV-FIB-NPY in the striatum following saline, initial 
ethanol, or test day ethanol injection (A). Between initial ethanol and test day ethanol 
locomotor activity measures, ethanol was administered in the home cage for a total 
of 10 trials but mice were not exposed to the locomotor chamber. Locomotor activity 
corrected for basal activity is presented in B and is used as the measure of ethanol-
induced locomotor activity. Ethanol-induced sensitization is presented as a change 
in activity on the ethanol test day from baseline ethanol activity following initial 
ethanol injections (C). Saline and initial ethanol baselines represent the average 
locomotor activity across 3 separate trials. Values are represented as mean ± SEM.   
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Figure 3.4 Raw locomotor activity during the first 5 minutes of a 20-minute session 
in DBA/2J mice infused with either PBS or rAAV-FIB-NPY in the striatum following 
saline, initial ethanol, or test day ethanol injection (A). Between initial ethanol and 
test day ethanol locomotor activity measures, ethanol was administered in the home 
cage for a total of 10 trials but mice were not exposed to the locomotor chamber. 
Locomotor activity corrected for basal activity is presented in B and is used as the 
measure of ethanol-induced locomotor activity. Ethanol-induced sensitization is 
presented as a change in activity on the ethanol test day from baseline ethanol 
activity following initial ethanol injections (C). Saline and initial ethanol baselines 
represent the average locomotor activity across 3 separate trials. Values are 
represented as mean ± SEM.  * indicates a significant effect of vector treatment (p 
< 0.05). 
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Figure 3.5 Raw locomotor activity during a 20-minute session in NPY -/- and NPY 
+/+ mice (A) and in males and females (B) following saline, initial ethanol, or test day 
ethanol injection. Between initial 2.0 g/kg ethanol and test day ethanol locomotor 
activity measures, a higher dose of ethanol (2.5 g/kg) was administered in the home 
cage for a total of 10 trials but mice were not exposed to the locomotor chamber. 
Values are represented as mean ± SEM.  * indicates a significant genotype 
difference while # indicates a significant gender effect (p < 0.05). 
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Figure 3.6 Locomotor activity in NPY -/- and NPY +/+ mice corrected for saline 
baseline activity as a measure of ethanol-induced locomotor activity (A). Ethanol-
induced locomotor sensitization is presented as a change in activity on the ethanol 
test day or final saline administration from activity following the initial ethanol 
injection. Values are represented as mean ± SEM. * indicates a significant effect of 
genotype (p < 0.05). 
 
-1500
-1000
-500
0
500
1000
1500
2000
2500
Ethanol Test Day
Final Saline
NPY -/-
NPY +/+
*
Lo
co
m
ot
or
 A
ct
iv
ity
C
ha
ng
e 
fr
om
 S
al
in
e 
B
as
el
in
e
(c
m
/2
0 
m
in
)
-1000
0
1000
2000
3000
NPY -/-
NPY +/+
Ethanol Test Day
Final Saline
*
*
Lo
co
m
ot
or
 A
ct
iv
ity
C
ha
ng
e 
fr
om
 E
th
an
ol
 B
as
el
in
e
(c
m
/2
0 
m
in
)
A)
B)
 
 86 
 
Figure 3.7 Raw locomotor activity during a 20-minute session in NPY Y1 -/- and 
NPY Y1 +/+ mice following saline, initial ethanol, or test day ethanol injection (A). 
Between initial ethanol and test day ethanol locomotor activity measures, ethanol 
was administered in the home cage for a total of 10 trials but mice were not exposed 
to the locomotor chamber. Locomotor activity corrected for basal activity is 
presented in B and is used as the measure of ethanol-induced locomotor activity. 
Ethanol-induced sensitization is presented as a change in activity on the ethanol test 
day from baseline ethanol activity following initial ethanol injections (C). Saline and 
initial ethanol baselines represent the average locomotor activity across 3 separate 
trials. Values are represented as mean ± SEM.  * indicates a significant effect of 
genotype (p < 0.05). 
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Figure 3.8 Raw locomotor activity during a 20-minute session in DBA/2J mice 
infused with either rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the nucleus accumbens 
core following saline, initial ethanol, or test day ethanol injection (A). Between initial 
ethanol and test day ethanol locomotor activity measures, ethanol was administered 
in the home cage for a total of 10 trials but mice were not exposed to the locomotor 
chamber. Locomotor activity corrected for basal activity is presented in B and is 
used as the measure of ethanol-induced locomotor activity. Ethanol-induced 
sensitization is presented as a change in activity on the ethanol test day from 
baseline ethanol activity following initial ethanol injections (C). Saline and initial 
ethanol baselines represent the average locomotor activity across 2-3 separate 
trials. Values are represented as mean ± SEM.   
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Figure 3.9 Raw locomotor activity during the first 10 minutes of a 20-minute session 
in DBA/2J mice infused with either rAAV-FIB-GFP or rAAV-FIB-NPY13-36 in the 
nucleus accumbens core following saline, initial ethanol, or test day ethanol injection 
(A). Between initial ethanol and test day ethanol locomotor activity measures, 
ethanol was administered in the home cage for a total of 10 trials but mice were not 
exposed to the locomotor chamber. Locomotor activity corrected for basal activity is 
presented in B and is used as the measure of ethanol-induced locomotor activity. 
Ethanol-induced sensitization is presented as a change in activity on the ethanol test 
day from baseline ethanol activity following initial ethanol injections (C). Saline and 
initial ethanol baselines represent the average locomotor activity across 2-3 
separate trials. Values are represented as mean ± SEM.  * indicates a significant 
effect of viral treatment (p < 0.05). 
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CHAPTER 4 
 
THE ROLE OF CHRONICALLY SECRETED AMYGDALAR NEUROPETIDE Y 
(NPY) IN ETHANOL CONSUMPTION AND ETHANOL DEPENDENCE 
 
 
 
Introduction 
 
According to a 2002 report from the World Health Organization, alcohol abuse 
is the third leading cause of preventable premature death in developing countries 
after tobacco and hypertension. In the United States, alcohol falls just behind 
tobacco and obesity as the root cause of death not exclusively related to genetic 
factors (McGinnis & Foege, 1993). Annually, alcohol abuse and alcoholism affect 
nearly 14 million Americans, result in more than 105,000 deaths, and cost 185 billion 
dollars (Harwood, Fountain, & Livermore, 1998). Thus, identifying the neurochemical 
basis for the development of alcohol addiction is the first step in the construction of 
effective pharmacological targets for treating alcohol abuse disorders. 
The effects of ethanol on many classic neurotransmitter systems have been 
described (Koob et al., 1998). However, with the exception of the opioids and 
peptides of the hypothalamic-pituitary-adrenal (HPA) axis (Froehlich & Li, 1993; 
Ogilvie, Lee, Weiss, & Rivier, 1998), relatively little is known of the role that other 
neuropeptides play in ethanol-seeking behavior. One interesting candidate is 
neuropeptide Y (NPY), a 36-amino-acid neuromodulator belonging to the PP-fold 
family of peptides (Berglund et al., 2003; Colmer & Wahlestedt, 1993; Dumont, 
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Martel, Fournier, St-Pierre, & Quirion, 1992). NPY is widely expressed throughout 
the central nervous system (Gray & Morley, 1986) and modulates a wide-range of 
neurobiological functions (Heilig & Widerlov, 1995). In recent years, several 
important observations have supported a role for NPY in the regulation of ethanol 
consumption (Pandey et al., 2003a; Thiele & Badia-Elder, 2003; Thiele et al., 2003; 
Thiele et al., 2004b). For example, a genetic linkage analysis conducted in F2 
intercross progenies of selectively bred alcohol-preferring (P) and non-preferring 
(NP) rat lines identified a chromosomal region that includes the gene for the NPY 
precursor (Bice et al., 1998; Carr et al., 1998). Interestingly, P rats and High Alcohol-
Drinking (HAD) rats have low levels of NPY in the amygdala when compared to 
controls (Ehlers et al., 1998; Hwang et al., 1999) and ventricular administration of 
NPY reduces high ethanol drinking in P and HAD rats without altering ethanol 
consumption in low or moderate ethanol drinking lines (Badia-Elder et al., 2003; 
Badia-Elder et al., 2001; Gilpin, Stewart, Murphy, & Badia-Elder, 2005; Gilpin et al., 
2003; Katner, Slawecki, & Ehlers, 2002a; Katner, Slawecki, & Ehlers, 2002b; 
Slawecki et al., 2000). Consistent with observations in rats, voluntary ethanol 
consumption and resistance to the intoxicating effects of ethanol are inversely 
related to NPY levels in genetically altered mice (Pandey et al., 2004; Thiele et al., 
2002; Thiele et al., 1998; Thiele et al., 2000a; Thiele et al., 2004a). 
The amygdala is crucial for coordinating behavioral, autonomic, and 
endocrine fear responses (Davis, 1998; Fendt & Fanselow, 1999; LeDoux, 2000) 
which are, in part, modulated by amygdalar NPY signaling (Heilig et al., 1993). The 
observations that P and HAD rats have decreased NPY levels in the amygdala 
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(Ehlers et al., 1998; Hwang et al., 1999) has led several investigators to assess the 
role of amygdalar NPY signaling in modulating ethanol consumption. However, 
studies that have assessed the role of amygdalar NPY on ethanol consumption have 
largely relied on procedures involving acute short-term alterations of NPY signaling 
in animals with an established history of ethanol exposure or dependence (Badia-
Elder, Gilpin, & Stewart, 2007; Katner et al., 2002a; Pandey et al., 2003b; Pandey, 
Zhang, Roy, & Xu, 2005; Schroeder, Olive, Koenig, & Hodge, 2003). An important 
issue not addressed by these experiments is the role of amygdalar NPY signaling in 
the acquisition of ethanol consumption over the entire history of ethanol exposure 
and throughout the development of ethanol dependence. In fact, it has been 
suggested that ethanol dependence stems, in part, from alterations of normal NPY 
signaling resulting from repeated cycles of abstinence and relapse (Koob, 2003; 
Koob & Le Moal, 2001).  
Thus, in this investigation we used a rAAV-FIB-NPY viral vector that promotes 
the constitutive secretion of NPY from transduced neurons to study the role of 
amygdalar NPY in ethanol consumption and ethanol dependence induced by chronic 
intermittent ethanol vapor exposure. This virus has been described elsewhere (Foti 
et al., 2007). We chose inbred C57BL/6J mice because this strain drinks large 
amounts of ethanol (Belknap et al., 1993; Yoneyama et al., 2008) and C57BL/6J 
mice have reduced amygdalar expression of NPY when compared to low ethanol 
drinking DBA/2J mice (Hayes et al., 2005). Further, to determine if the influence of 
the rAAV-FIB-NPY vector on ethanol drinking and/or dependence was brain-region 
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specific, we studied the effects of nucleus accumbens core transduction of the rAAV-
FIB-NPY vector on ethanol drinking.  
 
Methods 
 
Subjects 
Male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were 
3-6 months of age and weighed between 16.1 and 27.0 grams at the beginning of 
the experiments. Mice were housed individually in polypropylene cages with corncob 
bedding (Teklad, Madison, WI) and had ad libitum access to standard rodent chow 
(LabDiet, Brentwood, MO) and water except where noted. The colony room was 
maintained at 22ºC with a 12 hour:12 hour light:dark cycle. All procedures were 
conducted in compliance with the National Institute of Health guidelines and each 
protocol has been approved by the University of North Carolina Animal Care and 
Use Committee. 
 
Viral Vectors 
The AAV2 vectors were constructed as previously described (Haberman et 
al., 2003; McCown, 2006). Please refer to Chapter 3 for details of this procedure. 
AAV-FIB-NPY (3.3 x 1012 viral particles/ml), AAV-NPY (3.2 x 1012 viral particles/ml), 
and AAV-FIB-GFP (4.2 x 1012 viral particles/ml) were used in the following 
experiments. The AAV-FIB-NPY construct transduces neurons in vivo and 
constitutively secretes the gene product, NPY. The AAV-NPY construct expresses 
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NPY, but the NPY is not secreted from the transduced cell. Finally, the AAV-FIB-
GFP construct expresses and constitutively secretes GFP, serving as a control for 
non-therapeutic protein secretion.    
 
Assessment of ethanol consumption in C57BL/6J mice with increased 
synthesis and constitutive secretion of NPY in the amygdala or nucleus 
accumbens core 
 
Stereotaxic Surgery 
Approximately 2 weeks after arrival, mice were anesthetized with a cocktail of 
ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and infused bilaterally with one of 
the three viral vectors (n=16/group) via an injector designed to fit a 26 gauge 
cannula (Plastic One, Roanoke, VA). The infusion volume was 0.5µl/10-minutes/side 
in the core of the NAc and 1.0µl/10-minutes/side in the CeA delivered via 
microsyringe attached to a Harvard Apparatus PHD 2000 microinfusion pump. 
Infusion volumes were determined by pilot studies using a rAAV-GFP vector (Figure 
4.1). GFP expression was confined to the CeA and the NAc core using the infusion 
volumes above. We avoided a 1.0 µl dose in the NAc core because GFP was found 
to also express in the NAc shell with this volume. The following coordinates were 
used: 1.5 mm posterior to bregma, ± 2.8 mm lateral to midline, and 4.4 mm ventral 
to skull surface for the CeA and 1.4 mm anterior to bregma, ± 0.9 mm lateral to 
midline, and 4.7 mm ventral to skull surface for the NAc core. Animals were 
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monitored daily and allowed to recover for 7-10 days which ensured ample time for 
the transduction of the viral vectors. 
 
RT-PCR Validation of Vector Activity In Vivo 
 See appendix 1 for description of this methodology.  
 
Voluntary Ethanol Consumption 
Following recovery, mice were given access to ethanol via a two-bottle choice 
continuous-access paradigm by which animals had access to an ethanol solution in 
one bottle and water in the other bottle (Fee et al., 2004). Animals were presented 
with a 3% (v/v) solution of ethanol mixed in tap water for the first 4-days. The 
concentrations were then increased every 4-days as follows: 5, 8, 10, 13, 15, 18, 20, 
23, and 25% and then ramped back down to 10% ethanol using the same 
concentrations. Ethanol, water, and food consumption measures were taken every 2 
days along with body weight measures, at which time bottle positions were changed 
to prevent position preferences. Readings were uniformly taken immediately prior to 
lights-off (10:30 a.m.). 
Next, mice were presented with consumption of 16% ethanol versus water for 
8-days. Baseline readings were collected on days 7 and 8 for the study involving 
viral vector infusion into the CeA, and on day 8 for the study with vector infusion into 
the NAc core. Then ethanol was removed from the mouse cages for 2-weeks, at 
which time mice continued to receive ad libitum access to food and water. After 2-
weeks, 16% ethanol and water were returned to the mouse cages beginning 4-hours 
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prior to lights off and consumption measures were collected at 1-hour intervals for 6-
hours and then at 24- and 48-hours after ethanol was re-introduced to the mouse 
cages.  
 
Tissue Preparation and Verification of Injection site 
At the completion of each study, mice were given an i.p. injection of 
ketamine/xylazine cocktail (117 mg/kg and 7.92 mg/kg, respectively) and were then 
perfused transcardially with 0.1 mM phosphate-buffered saline (PBS; pH 7.4) 
followed by 4% paraformaldehyde in phosphate buffer. The brains were collected 
and post-fixed in paraformaldehyde for 4 hours at 4°C, at which point they were 
transferred to PBS. Brains were then sliced into 40 μm sections and stored at 4°C 
until immunohistochemical analyses. 
Astrocytes respond to brain injuries, including puncture wounds, by increasing 
the production of specific proteins including glial fibrillary acidic protein (GFAP). 
Implantation of a guide cannula into the cerebral cortex of Wistar rats induces the 
formation of reactive astrocytes which are concentrated immediately adjacent to the 
cannula tract and which are positive for GFAP (Cetin, Ball, Gokden, Cruz, & Dienel, 
2003). We used this technique to examine the track placements of our injectors by 
staining brain slices for the presence of GFAP immunoreactivity. To that end, tissue 
slices were washed in PBS and then blocked in a solution containing 0.1% Triton X-
100 and 10% goat serum for 1-hour. The slices were then incubated with polyclonal 
rabbit anti-GFAP antibody (DakoCytomation, Glostrup, Denmark; 1:1000) and 3% 
goat serum for approximately 72-hours at 4°C. After multiple PBS washes, slices 
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were incubated with biotinylated secondary antibody from the VectaStain rabbit ABC 
kit (Vector Laboratories, Burlingame, CA) and 3% goat serum for 1-hour at room 
temperature. Following several PBS washes, tissue slices were transferred to the 
VectaStain ABC reagent mixture and left for 1-hour, and were then stained using the 
DAB method (Vector Laboratories, Burlingame, CA) with 0.0063% H2O2, 0.05% 
DAB, 0.0075% NiAmSO4, and 0.005% CoCl2. Slices were mounted onto microslides 
using ShurMount mounting media (Durham, NC). Images were visualized using a 
Nikon Digital Sight DS-U1 camera attached to a Nikon Eclipse E400 microscope 
with 10X objective. Placement was verified according to the Franklin and Paxinos 
mouse brain atlas (Paxinos & Franklin, 2004).   
 
Data Analyses 
Because sex never interacted with viral vector treatment in any of the 
analyses described below, male and female data are collapsed in all graphical 
presentations of the data. For ethanol and food intake, grams consumed per 
kilogram of body weight were calculated for each mouse. Water consumption 
measures were expressed as milliliters consumed per kilogram of body weight. All 
data are represented as mean U+ U standard error of the mean (SEM). Data were 
analyzed using analysis of variance (ANOVA) and LSD tests were performed for 
post-hoc analyses. Significance was accepted at p<0.05 (two-tailed). 
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Assessment of ethanol consumption during repeated intermittent ethanol 
vapor exposure in C57BL/6J mice with increased synthesis and constitutive 
secretion of NPY in the amygdala 
 
Recombinant Adeno-Associated Viral Vector (rAAV-FIB-NPY) 
 The virus used in this experiment was a separate aliquot of the rAAV-FIB-
NPY described above. PBS infusions served as the control due to the lack of 
availability of the rAAV-FIB-GFP virus. 
 
Stereotaxic surgery 
Following 2 weeks of habituation, mice were anesthetized with a cocktail of 
ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and infused bilaterally with either 
PBS (N=18) or rAAV-FIB-NPY (N=17) at a volume of 1.0 μl per side at a rate of 0.1 
μl/min using the same parameters described above. The following coordinates were 
used: 1.5 mm posterior to bregma, ± 2.8 mm lateral to midline, and 4.4 mm ventral 
to skull surface. Animals were monitored daily and allowed to recover for 10 days 
which ensured ample time for the transduction of the viral vector. 
 
Voluntary Ethanol Consumption: Limited Access Paradigm 
Following recovery, mice were trained on a limited-access to a two-bottle 
choice paradigm using a modified sucrose fading procedure. Thirty minutes prior to 
lights out animals were given 2 hours of access to an ethanol/sucrose solution in 
one bottle and water in the other bottle. Animals were presented with a solution of 
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10% ethanol (v/v) and 5% sucrose (w/v) mixed in tap water versus water alone for 2 
days. The concentrations were then increased every 2-3 days as follows: 12.5% 
ethanol with 5% sucrose, 15% ethanol with 5% sucrose, 15% ethanol with 2% 
sucrose, and finally 15% ethanol alone for the duration of the experiment. 
Ethanol/sucrose and water consumption measures were taken daily with bottle 
positions alternated to prevent position preferences. Body weight and food 
consumption measures were taken every other day.  
 
Chronic Ethanol Vapor Exposure 
 After establishing a stable baseline of 15% ethanol consumption 
(approximately 45 days), mice were separated into two groups: chronic ethanol 
vapor exposure/withdrawal (N=19) or control air exposure (N=16). The ethanol 
group received four days of 16 hour continuous exposure to ethanol vapor inhalation 
with 8 hours of withdrawal following each vapor exposure. Control mice were 
exposed to air but were otherwise treated identically to the ethanol group. Chronic 
ethanol or air exposure was delivered via Plexiglas inhalation chambers modified 
from previously described (Becker & Lopez, 2004). Briefly, ethanol was volatilized by 
passing air through an air stone submerged in ethanol. The ethanol vapor was then 
mixed with fresh air and delivered to the chambers at levels which have been shown 
in our lab to yield BECs of 150-200 mg/dL. Prior to being placed in the chambers 
each day, mice received an i.p. injection of ethanol (1.5 g/kg) and the alcohol 
dehydrogenase inhibitor, pyrazole (1 mmol/kg), mixed in isotonic saline in order to 
initiate intoxication and stabilize blood ethanol concentrations. Mice placed in the air 
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chambers received i.p. injections of pyrazole in saline. Animals were exposed to 5 
cycles of 4 day exposures to ethanol vapor (16 hours per day) and withdrawal. Each 
cycle was separated by 5 days of limited access two-bottle choice consumption 
(15% ethanol vs. water). Between cycles 4 and 5 animals were allowed a two-week 
ethanol deprivation where food and water were available ad libitum.   
  
Open-Field Testing of Anxiety-Like Behavior 
 Approximately 24 hours after the final limited access ethanol consumption 
trial, mice were tested for anxiety-like behavior using the open-field locomotor 
activity monitors. All animals were transferred to the testing room and allowed at 
least 30 minutes to habituate to surroundings. A fan provided masking white noise 
and testing was conducted under ambient light. The chamber itself was made of 
clear Plexiglas which measured 40.64 X 40.64 X 30.48 centimeters. Activity was 
monitored via photobeam breaks (Harvard Apparatus, Inc., Holliston, MA) for 20 
minutes. Time spent and distance traveled in the center sections of the chamber 
were recorded as the measures of anxiety-like behavior with reduced center time 
and/or distance traveled in the center portion of the arena though to indicate higher 
levels of anxiety. This paradigm has been verified pharmacologically (Choleris, 
Thomas, Kavaliers, & Prato, 2001) and takes advantage of the natural survival 
instincts which limit access to predation. . 
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Data Analyses 
Because sex never interacted with viral vector treatment in any of the 
analyses described below, male and female data are collapsed in all graphical 
presentations of the data. Data were analyzed using analysis of variance (ANOVA) 
with all data represented as mean U+ U standard error of the mean (SEM). Significance 
was accepted at p<0.05 (two-tailed). 
 
Results 
 
Verification of Vector Transduction and Infusion Placement 
Previous work with the rAAV vectors involved rats (Haberman et al., 2003; 
McCown et al., 1996). Therefore, it was important to confirm that these viral vectors 
would transduce neurons in the mouse brain, specifically the amygdala. To this end, 
pilot studies were performed with a rAAV-GFP vector (which promotes expression, 
but not secretion, of GFP in transduced cells). As can be seen in Figures 3.1 and 
4.1, GFP was expressed locally in the nucleus accumbens core and central nucleus 
of the amygdala (CeA) in rAAV-GFP treated mice using injection volumes noted 
above. These observations confirm that our rAAV vectors transduced in cells of CeA 
of C57BL/6J mice. To confirm vector placement, we directly examined the lesion 
tract produced by the injector which was identified by GFAP immunoreactivity 
(Figure 4.2). Further, the duration of vector activity in vivo was validated by 
demonstrating the presence of vector derived mRNA in microdissected amygdalar or 
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nucleus accumbens tissue at 2 weeks or approximately 3.5 months following 
infusion (Appendix 1; Figures A.1 and A.2) 
 
Effect of chronic amygdalar transduction of NPY on ethanol consumption by 
C57BL/6J mice 
Exposure to a range of ethanol concentrations during the first 64-days of 
ethanol access revealed no significant differences in average ethanol consumption 
between groups treated with the rAAV-FIB-GFP (15.39 U+ U 1.14 g/kg/day), rAAV-FIB-
NPY (14.99 U+ U 1.18 g/kg/day), or rAAV-NPY (16.39 U+ U 1.22 g/kg/day) vectors. 
Similarly, the rAAV-FIB-GFP, rAAV-FIB-NPY, and rAAV-NPY groups did not differ 
significantly in water consumption (70.47 U+ U 5.16 ml/kg/day, 60.68 U+ U 5.39 ml/kg/day, 
and 62.97 U+ U 5.54 ml/kg/day, respectively) or food intake (172.79 U+ U 5.87 g/kg/day, 
171.97 U+ U 6.06 g/kg/day, and 184.03 U+ U 6.28 g/kg/day, respectively). 
Following approximately 2-months of ethanol access, significant differences 
between groups became evident. Figure 4.3 shows cumulative ethanol (A) and 
water (B) consumption for the first 6-hours after ethanol was first returned following 
the 2-week deprivation period. A two-way (sex x vector) ANOVA performed on the 
total 6-hour consumption data revealed a significant effect of vector treatment [F(3,43) 
= 3.82; p = 0.040]. To determine the duration of group differences over the 6-hour 
test, post hoc LSD tests performed at each time-point showed that the rAAV-FIB-
NPY group drank significantly less ethanol than rAAV-FIB-GFP treated mice during 
hours 3-6 of the test, while the rAAV-NPY group did not differ significantly from the 
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rAAV-FIB-GFP treated mice. An ANOVA performed on the total 6-hour water intake 
data revealed no significant effects. 
Figure 4.4A shows ethanol consumption by mice on the last 2-days before the 
2-week ethanol deprivation (hours -48 and -24) and the first 2-days that ethanol was 
returned following the deprivation period (hours 24 and 48). A repeated-measures 
(days x sex x vector) ANOVA performed on pre- and post-deprivation data revealed 
a significant main effect of vector condition [F(2,39) = 4.05; p = 0.025] and a significant 
main effect of sex [F(1,39) = 50.16; p = 0.001]. Additionally, the days main effect was 
significant [F(3,117) = 9.72; p = 0.001]. LSD tests performed on the vector main effect 
showed that relative to the rAAV-FIB-GFP and rAAV-NPY treated groups, mice 
treated with the rAAV-FIB-NPY vector drank significantly less ethanol. Figures 4.4B 
and 4.4C show water intake and body weight measures before and after the 2-week 
ethanol deprivation period. ANOVAs performed on water intake and body weight 
data failed to achieve statistical significance. Thus, transduction of the rAAV-FIB-
NPY vector into the CeA significantly reduced ethanol intake in mice with an 
extended history of ethanol consumption. On the other hand, the rAAV-FIB-NPY 
vector did not alter water consumption or body weights. 
 
Effect of chronic NPY Transduction in the NAc Core on Ethanol Consumption by 
C57BL/6J Mice 
During the 64-days of two-bottle access to ethanol and water there were no 
significant differences in average ethanol consumption between groups treated with 
NAc core infusion of the rAAV-FIB-GFP (16.24 U+ U 0.98 g/kg/day), rAAV-FIB-NPY 
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(16.26 U+U 0.91 g/kg/day), or rAAV-NPY (16.99 U+ U 0.98 g/kg/day) vectors. Similarly, 
rAAV-FIB-GFP, rAAV-FIB-NPY, and rAAV-NPY groups did not differ significantly in 
water consumption (59.22 U+ U 3.68 ml/kg/day, 66.20 U+ U 3.44 ml/kg/day, and 66.17 U+ U 
3.68 ml/kg/day, respectively) or food intake (180.59 U+ U 7.48 g/kg/day, 189.79 U+ U 7.00 
g/kg/day, and 187.19 U+ U 7.48 g/kg/day, respectively).  
Contrary to what was observed when vectors were injected into the CeA, viral 
vector infusion into the NAc core did not influence voluntary ethanol intake in mice 
after long-term ethanol access, neither before nor after a 2-week ethanol deprivation 
period (Figure 4.5A). A repeated-measures (days x sex x vector) ANOVA performed 
on pre- and post-deprivation ethanol consumption data revealed a significant main 
effect of sex [F(1,38) = 33.97; p = 0.001]. Additionally, the days main effect was 
significant [F(2,76) = 38.14; p = 0.001]. LSD tests performed on the days main effect 
showed that mice drank significantly less ethanol after the 2-week deprivation period 
relative to pre-deprivation consumption. This apparent “inverse alcohol deprivation 
effect” has been described previously in mice (Salimov, Salimova, Ratkin, Shvets, & 
Maisky, 1995). Vector transduction of the NAc core also produced no significant 
effects of water intake (Figure 4.5B) or body weight (Figure 4.5C) before or after 
ethanol deprivation.  
 
Effect of chronic amygdalar NPY transduction on limited access ethanol 
consumption during chronic intermittent ethanol vapor exposure in C57BL/6J mice 
 A repeated-measures (sex x viral treatment x vapor exposure) ANOVA 
performed on the ethanol consumption variable indicated that there was a main 
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effect of sex on ethanol consumption [F(1,27) = 9.12; p =0.005] such that female mice 
consumed more ethanol than males. However, there were no main effects of either 
viral treatment [F(1,27) = 3.20; p = 0.085] or ethanol vapor exposure [F(1,27) = 0.04; p = 
0.852] (Figure 4.6A). Additionally, the same pattern holds true for water consumption 
as there was a significant main effect of sex where females consumed more water 
[F(1,27) = 9.44; p = 0.005] but there were no effects viral treatment [F(1,27) = 1.08; p = 
0.307] or ethanol vapor exposure condition [F(1,27) = 0.83; p = 0.372] (Figure 4.6B).  
 
Effect of chronic intermittent ethanol vapor exposure and withdrawal on anxiety-like 
behavior in C57BL/6J mice with amygdalar transduction of NPY 
 A three way (sex x viral treatment x vapor exposure) ANOVA indicated that 
multiple cycles of exposure to ethanol vapor and withdrawal significantly decreased 
the amount of time spent in the center section of the open field [F(1,27) = 4.99 ; p = 
0.034] suggesting that multiple cycles of ethanol vapor exposure and withdrawal 
promote increased anxiety-like behavior in C57BL/6J mice (Figure 4.6A). Neither 
sex [F(1,27) = 0.03; p = 0.867] nor viral treatment [F(1,27) = 0.03 ; p = 0.868] had an 
effect on center time. Further, there were no significant differences between sex 
[F(1,27) = 3.26; p = 0.082], viral treatment [F(1,27) = 0.22; p = 0.640], or vapor exposure 
[F(1,27) = 0.001; p = 0.975] on center distance traveled (Figure 4.6B). 
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Discussion 
 We have made three important observations in the present investigation. (1) 
rAAV-FIB-NPY transduction of the CeA, but not rAAV-NPY transduction, significantly 
reduced ethanol drinking by C57BL/6J mice when compared to rAAV-FIB-GFP mice, 
but only after approximately 2-months of ethanol drinking. Neither the rAAV-FIB-
NPY nor the rAAV-NPY vectors altered water drinking, food intake, or body weight 
when injected into the CeA. (2) The rAAV-FIB-NPY transduction of the NAc core did 
not alter ethanol or water drinking, food intake, or body weight relative to rAAV-FIB-
GFP treated mice, a finding that verifies site-specificity of the effect of the rAAV-FIB-
NPY vector on ethanol intake. (3) Mice exposed to repeated intermittent ethanol 
vapor and withdrawal failed to exhibit the increased ethanol consumption 
characteristic of ethanol dependence but did display withdrawal-induced anxiety-like 
behavior as measured by the open-field activity test. However, contrary to 
expectations, the rAAV-FIB-NPY vector failed to protect against withdrawal-induced 
anxiety-like behavior. Together, these results suggest that increased NPY signaling 
in the CeA selectively reduces ethanol drinking in high ethanol drinking C57BL/6J 
mice with an extensive history of ethanol exposure independent of changes in water 
consumption, body weight, or feeding behavior.  
 A potentially key observation in the present work was that rAAV-FIB-NPY 
transduction of the CeA reduced ethanol drinking in mice but only after an extensive 
history of ethanol consumption. Such a mechanism has been demonstrated in 
previous work. Specifically, following long-term consumption of ethanol with periods 
of imposed ethanol abstinence, NPY-induced reductions in ethanol drinking are 
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enhanced in ethanol-preferring P rats relative to non-dependent animals (Badia-
Elder et al., 2007). These observations suggest the possibility that treatments which 
increase NPY signaling can modulate ethanol intake but only in animals that have 
become ethanol-dependent as a result of long-term access to ethanol consumption. 
However, the reductions in ethanol consumption following chronic amygdalar NPY 
secretion observed in this experiment were rather modest. Since these mice were 
exposed to chronic secretion of NPY, it is possible that the effects of NPY on ethanol 
consumption are being blunted by changes in receptor numbers or distribution due 
to compensation. Furthermore, NPY may only play a partial role in ethanol 
consumption and future research should more thoroughly investigate other potential 
players.  
 Furthermore, we expected to also show that intra-amygdalar administration of 
the rAAV-FIB-NPY would also protect against the increased ethanol consumption 
typically exhibited following exposure to repeated cycles of ethanol vapor and 
withdrawal. Consistent with this hypothesis, Wistar rats exposed to ethanol vapor for 
8-weeks show reduced ethanol drinking in response to centrally infused NPY. 
However, NPY infusion did not modulate ethanol intake in rats that were not 
exposed to ethanol vapor and were therefore not ethanol-dependent (Thorsell et al., 
2005). Similarly, a recent report found that amygdalar infusion of a Sindbis viral 
vector containing NPY cDNA protected against increased ethanol intake following 
repeated ethanol exposed and abstinence in Wistar rats (Thorsell et al., 2007). 
Further, in Wistar rats given long-term intermittent exposure to ethanol vapor, central 
infusion of a selective Y2-receptor antagonist (BIIE0246) suppresses operant 
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responding for ethanol at a dose that is ineffective in rats not exposed to ethanol 
vapor (Rimondini, Thorsell, & Heilig, 2005). 
 However, despite the fact that increased ethanol self-administration in ethanol 
vapor-exposed rodents relative to non-vapor exposed mice has been reported by 
several research groups (Becker & Lopez, 2004; Chu, Koob, Cole, Zorrilla, & 
Roberts, 2007; Finn et al., 2007; Valdez et al., 2002), none of our experimental 
conditions exhibited this typical indicator of ethanol dependence. The reason for this 
lack of effect is unknown. Multiple studies performed in our laboratory have shown 
BECs in the target range of 150-200 mg/dL under our specific parameters and these 
levels should be sufficient to elicit ethanol dependence (Becker & Lopez, 2004; 
Gilpin et al., 2008c; Lopez & Becker, 2005; Rimondini et al., 2005). In fact, some 
studies report dependence induced increases in ethanol consumption arising from 
ethanol-vapor-maintained BECs as low as 90-130 mg/dL (Chu et al., 2007; Finn et 
al., 2007). A dominating thought is that multiple cycles of ethanol access and 
withdrawal augment the development of dependence. Specifically, multiple 
withdrawals from cycles of chronic alcohol exposure have been shown to sensitize 
withdrawal-induced anxiety-like behaviors (Breese, Overstreet, & Knapp, 2005; 
Overstreet, Knapp, & Breese, 2002; Overstreet, Knapp, & Breese, 2004). However, 
our animals were exposed to 5 cycles of ethanol vapor and withdrawal without a 
subsequent effect on ethanol consumption. Others have reported vapor-induced 
increases in ethanol consumption with as few as 1-2 exposures (Becker & Lopez, 
2004; Chu et al., 2007).  
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 Interestingly, the fact that vapor exposed mice, regardless of viral treatment, 
exhibited increased anxiety-like behavior following withdrawal is consistent with 
other reports (Kotlinska & Bochenski, 2008; Overstreet et al., 2004). However, it is 
surprising that amygdalar infusion of rAAV-FIB-NPY did not reduce withdrawal-
induced anxiety-like behavior in C57BL/6J mice. This is unexpected for several 
reasons. First, acute NPY is known to possess anxiolytic properties when infused 
centrally and into the amygdala (Heilig, 1993; Heilig, Soderpalm, Engel, & Widerlov, 
1989). Second, rats show decreased NPY immunoreactivity in the amygdala 24 
hours after withdrawal from chronic ethanol exposure (Roy & Pandey, 2002). Third, 
following chronic ethanol exposure, mutant mice lacking NPY display elevated 
anxiety-like responses (Sparta, Fee, Knapp, Breese, & Thiele, 2007). This 
discrepancy could be due to background strain effects as the NPY -/- mice 
mentioned above were maintained on a 129/SvEv while the current mice were 
C57BL/6J mice. Further, results from anxiety experiments may depend on the 
paradigm used to test anxiety-like behavior (Fee et al., 2004). Lastly, as with any 
chronic drug administration, we need to address the possibility that compensatory 
alterations in other NPY receptors masked the ability of NPY to be protect against 
withdrawal-induced anxiety.   
 Consistent with the present observations, several lines of evidence indicate 
that NPY signaling in the amygdala is involved in regulating ethanol consumption. As 
mentioned above, the P and HAD rats have altered levels of NPY in several brain 
regions, but the most consistent observation between these high ethanol drinking 
lines is decreased NPY levels in the amygdala (Ehlers et al., 1998; Hwang et al., 
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1999). A more recent observation found that P rats have lower NPY in the CeA and 
medial amygdala (MeA), but not in the basolateral amygdala (BLA), when compared 
in NP rats (Pandey et al., 2005). Interestingly, infusion of a protein kinase A (PKA) 
activator (a treatment which increases NPY synthesis) or NPY into the CeA of P rats 
decreases ethanol intake and protects against elevated anxiety-like behavior that is 
characteristic of P rats (Pandey et al., 2005). Similarly, infusion of a PKA inhibitor 
into the CeA of Sprague-Dawley rats causes local reductions of NPY levels and is 
associated with increased anxiety-like behavior and increased ethanol consumption 
(Pandey et al., 2003b). Elevated anxiety-like behavior and ethanol drinking are 
prevented by co-administration of NPY into the CeA. Importantly, NPY does not 
affect ethanol consumption by rats not treated with the PKA inhibitor and which have 
unaltered amygdalar NPY levels (Pandey et al., 2003b). Recently, it was reported 
that bilateral injections into the CeA with a NPY-antisense vector significantly 
increases ethanol intake while injection into the CeA of a vector encoding NPY 
decreases ethanol drinking in Long-Evans rats displaying high levels of anxiety-like 
behavior. However, neither vector influenced ethanol intake by rats displaying low 
anxiety-like behavior (Primeaux, Wilson, Bray, York, & Wilson, 2006).  
 A role for amygdalar NPY signaling in the modulation of ethanol consumption 
has also been demonstrated in mice. NPY overexpressing mice show increased 
NPY expression that is restricted to the amygdala and cortex and these mice drink 
low amounts of ethanol relative to control mice (Thiele et al., 1998). Consistently, 
partial deletion of the CREB gene promotes increased ethanol drinking associated 
with reduced NPY expression in regions including the amygdala (Pandey et al., 
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2004). Finally, we have shown that high ethanol drinking C57BL/6J mice have low 
NPY levels in CeA and BLA when compared with low ethanol drinking DBA/2J mice 
(Hayes et al., 2005). Taken together, the present observations and those in previous 
reports suggest that low NPY signaling within the amygdala, and specifically within 
the CeA, promotes excessive ethanol intake which is rescued by treatments which 
augment NPY levels. Furthermore, several observations above indicate that NPY 
may influence ethanol consumption by regulating basal levels of anxiety (Pandey et 
al., 2003b; Pandey et al., 2005; Primeaux et al., 2006). However, there are several 
observations that are inconsistent with the above literature. NPY administered into 
the CeA of Wistar rats fails to alter ethanol drinking (Katner et al., 2002a) while CeA 
infusion of the Y1 receptor antagonist, BIBP 3226, into Long Evans rats significantly 
reduces ethanol reinforced lever pressing (Schroeder et al., 2003). It may be that 
low levels of amygdalar NPY (inherent or pharmacologically-induced) are necessary 
to show NPY-induced reductions of ethanol drinking.  
 In rodents, periodic deprivation from ethanol is commonly found to promote a 
transient increase in ethanol consumption relative to pre-deprivation levels. This 
phenomenon has been labeled the alcohol deprivation effect (ADE) and is thought to 
model compulsive uncontrolled relapse drinking characteristic of alcohol dependent 
humans (Spanagel & Holter, 1999). The ADE has been well characterized in rats 
(Heyser, Schulteis, & Koob, 1997; McKinzie et al., 1998; Rodd-Henricks et al., 2001; 
Rodd et al., 2003; Wolffgramm & Heyne, 1995) and has been observed in mice 
(Cowen, Schumann, Yagi, & Spanagel, 2003; Melendez, Middaugh, & Kalivas, 2006; 
Sanchis-Segura et al., 2006), although an “inverse ADE”, indicative of decreased 
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ethanol consumption following a deprivation period, has also been reported with 
mice (Salimov et al., 1995). In the present report, an ADE was not evident in the 
study involving viral vector infusion into the CeA (Figure 3). Furthermore, in the 
study involving vector injections into the NAc core, mice drank less ethanol following 
the 2-week ethanol deprivation (Figure 4), consistent with a reported “inverse ADE” 
(Salimov et al., 1995). While factors contributing to discrepancies are unclear, 
differences such as the duration of ethanol access and deprivation, the number of 
deprivation cycles, the concentration of ethanol used, and mouse strain are all 
possible explanations for differences between studies. 
The NAc has been implicated in reward, motivation, and the reinforcing 
effects of ethanol (Di Chiara & Imperato, 1988; Koob, 2003; Koob & Le Moal, 2001). 
Because infusion of NPY into the NAc supports a conditioned place preference, 
which suggests that NPY signaling in this region is reinforcing (Josselyn & Beninger, 
1993), it was somewhat surprising that infusion of the rAAV-FIB-NPY vector into the 
core of the NAc did not influence voluntary ethanol consumption in C57BL/6J mice. 
Importantly, the NAc core receives dopaminegic afferents from the lateral ventral 
tegmental area (VTA) and primarily projects to motor control brain regions such as 
the substantia nigra and dorsal striatum. However, the NAc shell interacts with the 
medial and lateral ventral tegmental areas through dopaminergic connections and is 
typically classified as a component of the extended amygdala (Haber, Fudge, & 
McFarland, 2000; Koob, 2003; Zahm, 1999; Zahm, 2000; Zahm, Jensen, Williams, & 
Martin, 1999). Thus, we speculate that the NAc shell may be a more likely target in 
which the rAAV-FIB-NPY vector will protect against increased ethanol intake by 
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C57BL/6J mice. Consistent with this view, high ethanol drinking C57BL/6J mice 
have significantly lower levels of NPY in the shell, but not the core, of the NAc when 
compared to low ethanol drinking DBA/2J mice (Hayes et al., 2005; Misra & Pandey, 
2003), and reduction of NPY levels in the NAc shell via a PKA inhibitor promotes 
increased ethanol drinking by Sprague-Dawley rats, an effect that is blocked by co-
infusion of NPY (Misra & Pandey, 2006).  
 In conclusion, the novel finding of the present report indicates that chronic 
overexpression and constitutive secretion of NPY influences ethanol consumption by 
high ethanol drinking C57BL/6J mice in a brain-region specific manner. Thus, the 
rAAV-FIB-NPY vector reduced voluntary consumption of ethanol after CeA 
transduction, but only after an extensive history of ethanol drinking. On the other 
hand, rAAV-FIB-NPY transduction of the NAc core did not alter ethanol drinking, a 
finding that verifies the site-specific effect of the rAAV-FIB-NPY vector on this 
phenotype. Future studies will determine if rAAV-mediated overexpression of NPY 
will attenuate increased ethanol drinking when injected into other brain regions of 
C57BL/6J mice and if the rAAV-FIB-NPY vector modulates other neurobiological 
responses to ethanol. 
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Figure 4.1 Photomicrographs of 50 μm coronal slices cut through the amygdala of 
C57BL/6J mice given site-directed infusion of a rAAV-GFP vector aimed at the 
central nucleus of the amygdala (CeA) (0.5 μl). Ten days after infusion mice were 
perfused and their brains removed. Slices display strong expression of GFP in cell 
bodies and terminals, a finding that verifies that the rAAV vector is transduced into 
the CeA of C57BL/6J mice. Images were photographed using 10x and 20x 
objectives. 
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Figure 4.2 Representative photomicrographs of 40 μm coronal slices cut through the 
amygdala of a non-infused control (A) and a rAAV-FIB-NPY vector-infused 
C57BL/6J mouse (B). Slices were stained for Glial Fibrillary Acidic Protein (GFAP), a 
marker of astrocyte reactivity following puncture wound. Images were photographed 
using a 10x objective. Abbreviations: BLA = basolateral amygdala; CeA = central 
nucleus of the amygdala. 
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Figure 4.3 Effect of CeA transduction by a rAAV-FIB-NPY vector on cumulative 
consumption of a 16% (v/v) ethanol solution (A) and water intake (B) by C57BL/6J 
ice for the first 6-hours after ethanol was returned immediately following a 2-week 
ethanol deprivation period. Values are expressed as mean U+ U SEM. * significantly 
different from rAAV-FIB-GFP group (P < 0.05). 
1 2 3 4 5 6
0
1
2
3
4
rAAV-FIB-GFP
rAAV-FIB-NPY
rAAV-NPY
Time following return of ethanol access (h)
* *
*
*
C
um
ul
at
iv
e 
16
%
et
ha
no
l i
nt
ak
e 
(g
/k
g)
1 2 3 4 5 6
0
5
10
15
20
25
Time following return of ethanol access (h)
C
um
ul
at
iv
e 
w
at
er
in
ta
ke
 (m
l/k
g)
A)
B)
 
 
 
 
 
 
 116 
 
Figure 4.4 Effect of CeA transduction by a rAAV-FIB-NPY vector on consumption of 
a 16% (v/v) ethanol solution (A) water intake (B) and body weight (C) by C57BL/6J 
mice on the last 2-days before the 2-week ethanol deprivation (hours -48 and -24) 
and the first 2-days that ethanol was returned following the deprivation period (hours 
24 and 48). Values are expressed as mean U+ U SEM. * indicates significant difference 
from groups rAAV-FIB-GFP and rAAV-NPY (P < 0.05).  
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Figure 4.5 Effect of NAc core transduction by a rAAV-FIB-NPY vector on 
consumption of a 16% (v/v) ethanol solution (a) water intake (b) and body weight (c) 
by C57BL/6J mice on the last day before the 2-week ethanol deprivation (hour -24) 
and the first 2-days that ethanol was returned following the deprivation period (hours 
24 and 48). Values are expressed as mean U+ U SEM.  
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Figure 4.6 Effect of amygdalar (CeA) transduction by a rAAV-FIB-NPY vector on 
limited access ethanol consumption of a 15% (v/v) ethanol solution (A) and water (B) 
following multiple cycles of ethanol vapor exposure and withdrawal (represented by 
the dashed lines). Values are expressed as mean U+ U SEM. 
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Figure 4.7 Effect of multiple cycles of ethanol vapor exposure and withdrawal on 
open field anxiety measures including time spent in the center (A) and distance 
traveled in the center (B). Values are expressed as mean U+ U SEM. * indicates 
significant difference at p < 0.05. 
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CHAPTER 5 
 
GENERAL DISCUSSION 
 
Summary of Experimental Findings 
 
 The overarching purpose of the studies detailed herein was to contribute to 
the existing knowledge of the role of NPY signaling in modulating behavioral and 
neurobiological responses to ethanol. In our first set of experiments, we utilized a 
mutant mouse model of modified protein kinase A signaling (RIIβ -/- mice) known to 
display enhanced sensitivity to the locomotor stimulant properties of ethanol and 
ethanol-induced behavioral sensitization (Fee et al., 2006; Fee et al., 2004; Thiele et 
al., 2000). Because recent evidence suggested that PKA may promote NPY 
synthesis (Dohrman, Chen, Gordon, & Diamond, 2002; Ginty, Bading, & Greenberg, 
1992; Pandey, Mittal, Lumeng, & Li, 1999; Pandey, Roy, Zhang, & Xu, 2004; Zhang 
& Pandey, 2003), we predicted that the altered neurobiological responses to ethanol 
observed in RIIβ -/- mice may be associated with modifications in NPY signaling in 
key brain regions associated with responses to drugs of abuse. To that end, an 
analysis of NPY mRNA and protein levels in multiple brain regions of RIIβ -/- and 
RIIβ +/+ mice indicated that RIIβ -/- mice exhibit a basal increase in NPY signaling in 
the hypothalamus (mRNA), nucleus accumbens core (Immunoreactivity: IR), 
ventromedial striatum (IR), and ventrolateral striatum (IR) compared to wildtype 
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mice. Further, acute ethanol administration led to a significant decrease in NPY IR 
when compared to saline-treated mice in the ventromedial and ventrolateral 
striatum, an effect that was independent of genotype.   
 Importantly, the core of the nucleus accumbens and the striatum are brain 
areas known to be involved in the regulation of motor behaviors (Herrero, Barcia, & 
Navarro, 2002; Kelley, 1999; Nicola, Surmeier, & Malenka, 2000; Zahm, 1999; 
Zahm, 2000). Therefore, we hypothesized that the enhanced NPY signaling in these 
regions may contribute to the potentiation of ethanol-induced locomotor responses 
characteristic of RIIβ -/- mice. Accordingly, the second set of experiments utilized 
recombinant adeno-associated viruses in inbred DBA/2J mice as well as genetic 
knockout animals to examine the effect of NPY signaling on ethanol-induced 
locomotor activity and/or behavioral sensitization.  
Pharmacologically, we showed that infusion of a viral vector which promotes 
the synthesis and constitutive secretion of NPY in vivo (rAAV-FIB-NPY) into the 
nucleus accumbens core of DBA/2J mice was associated with enhanced sensitivity 
to the locomotor stimulant effects of ethanol following repeated ethanol 
administration relative to control treatment. Consistently, nucleus accumbens core 
infusion of the rAAV-FIB-NPY13-36 viral vector, which theoretically blunts endogenous 
NPY signaling via agonist activity at the Y2 presynpatic autoreceptors, reduced 
ethanol-induced locomotor activity in DBA/2J mice relative to control treatment. 
Conversely, infusion of the rAAV-FIB-NPY vector into the striatum of DBA/2J 
protected against the development of ethanol-induced locomotor sensitization 
suggesting that the effects of NPY on ethanol-induced locomotor behaviors are brain 
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region-dependent. Further, mutant mice lacking the NPY gene displayed reduced 
ethanol-induced locomotor activity and locomotor sensitization relative to wildtype 
mice indicating that NPY -/- mice are less sensitive to the locomotor activating and 
sensitizing effects of ethanol. Interestingtly, mice lacking the NPY Y1 receptor 
exhibited an enhanced ethanol-induced locomotor sensitization relative to wildtype 
mice implicating a role for the Y1 receptor in locomotor responses to ethanol. To our 
knowledge, we provide the first evidence directly implicating NPY and its Y1 receptor 
in ethanol-induced locomotor activity and/or ethanol-induced behavioral 
sensitization.    
 The final set of experiments was designed to further investigate the role of 
amygdalar NPY signaling in ethanol consumption and ethanol-dependence. 
Previous research has implicated NPY signaling in the amygdala in neurobiological 
responses to ethanol (Ehlers et al., 1998; Hwang, Zhang, Ehlers, Lumeng, & Li, 
1999) but the majority of experimental manipulations utilized only acute, short-term 
alterations in NPY signaling in animals with an already established history of ethanol 
exposure (Badia-Elder, Gilpin, & Stewart, 2007; Katner, Slawecki, & Ehlers, 2002; 
Pandey, Roy, & Zhang, 2003; Schroeder, Olive, Koenig, & Hodge, 2003). 
Importantly, it has been suggested that a dysregulation of NPY signaling resulting 
from multiple cycles of ethanol exposure and withdrawal may underlie the 
development of ethanol dependence (Koob, 2003; Thorsell et al., 2007). Therefore, 
we examined the role of chronic amygdalar NPY secretion using the rAAV-FIB-NPY 
vector to provide long-term, stable, constitutive secretion of NPY during the 
acquisition of ethanol consumption and/or dependence.   
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 Interestingly, rAAV-FIB-NPY transduction in the central nucleus of the 
amygdala significantly reduced ethanol drinking by C57BL/6J mice when compared 
to rAAV-FIB-GFP treated mice, but only after approximately 2-months of ethanol 
consumption and a 2-week withdrawal period. Importantly, this effect was specific to 
the amygdala as rAAV-FIB-NPY transduction in the core of the nucleus accumbens 
did not alter ethanol intake relative to rAAV-FIB-GFP treated mice. Therefore, 
amygdalar NPY signaling may modestly contribute to the modulation of voluntary 
ethanol consumption in C57BL/6J mice, but only after a long history of ethanol 
consumption. Conversely, multiple cycles of ethanol vapor exposure and withdrawal 
failed to yield the characteristic increases in ethanol consumption inidicative of 
ethanol dependence (Becker & Lopez, 2004; Chu, Koob, Cole, Zorrilla, & Roberts, 
2007; Dhaher, Finn, Snelling, & Hitzemann, 2008), in mice given amygdalar infusion 
of the rAAV-FIB-NPY or control vector. However, this manipulation was able to elicit 
enhanced withdrawal-induced anxiety-like behavior as measured by the open-field 
activity test, specifically in ethanol vapor-exposed mice. Contrary to predictions 
though, amygdalar infusion of the rAAV-FIB-NPY vector failed to protect against the 
observed withdrawal-induced anxiety-like behavior. Together, these results suggest 
that increased NPY signaling in the CeA selectively reduces ethanol drinking in 
C57BL/6J mice with an extensive history of voluntary ethanol consumption. 
However, before further statements can be made, the role of chronic amygdalar 
NPY secretion needs to be addressed in a more robust paradigm of ethanol 
dependence capable of eliciting dependence-induced increases in drinking. 
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 Results from the present set of experiments raise the possibility that NPY is 
involved in separate neurobiological responses to ethanol via distinct circuitries, 
receptor subtypes, and interactions with other neurotransmitter systems. 
Specifically, NPY signaling in the nigrostriatal brain pathways modulates ethanol-
induced locomotor responses while NPY signaling in the mesolimbic pathways is 
involved in ethanol consumption behaviors.  
 
The Role of NPY in Ethanol-Induced Locomotor Activity 
and Ethanol-Induced Behavioral Sensitization 
 
Administration of most drugs of abuse is known to stimulate locomotion in 
rodents (Wise, 1988). This enhanced locomotor activation in rodents following drug 
exposure is thought to model the disinhibiting and euphoric effects of drugs of abuse 
in humans thereby providing a method of determining the neurobiological correlates 
of rewarding drug effects (Phillips, Roberts, & Lessov, 1997). Further, it has been 
suggested that drug-induced locomotor sensitization in animals may be a model for 
human addiction. Specifically, it is thought that neuroadaptations within crucial 
dopaminegic pathways in the brain resulting from repeated exposure to a drug lead 
to a hypersensitized drug craving, which promotes a vulnerability to relapse 
(Robinson & Berridge, 1993). In accordance with the idea that ethanol-induced 
locomotor sensitization may provide a model by which to evaluate the 
neurobiological correlates of ethanol addiction, Lessov et. al. (2001) showed that 
C57BL/6J mice which displayed ethanol-induced locomotor sensitization voluntarily 
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consumed higher amounts of ethanol relative to non-sensitized controls and relative 
to pre-sensitization drinking levels. Further, when typically low ethanol consuming 
DBA/2J mice are exposed to chronic ethanol injection prior to a two-bottle choice 
ethanol self-administration procedure, DBA/2J mice consumed similar amounts of a 
5% ethanol solution as the high ethanol consuming C57BL/6J mice in the same 
pretreatment conditions (Camarini & Hodge, 2004).   
The results of the experiments presented herein revealed that mice lacking 
NPY exhibited reduced ethanol-induced locomotor activity and ethanol-induced 
locomotor sensitization while NPY Y1 -/- mice displayed an enhanced ethanol-
induced locomotor sensitization compared to respective wildtype control mice.  
While these results clearly implicate NPY and the NPY Y1 receptor in ethanol-
induced locomotor behaviors, the reason for the opposite effects in the different 
genetic knockouts remains unclear. However, it is likely that compensatory changes 
in the receptor expression levels of other NPY receptor subtypes in the NPY Y1 -/- 
mice may contribute to the noted differences between experiments. Taken together, 
the results from the genetic knockout experiments suggest a relationship whereby 
modifications of NPY signaling lead to altreations in ethanol-induced locomotor 
behaviors.       
Consistent with this hypothesis, results from experiments utilizing viral vector 
infusion into the core of the NAc of DBA/2J mice reveal a pattern suggesting that 
increased NPY signaling in the NAc core promotes enhanced ethanol-induced 
locomotor behavior. Specifically, NAc core infusion of the rAAV-FIB-NPY enhanced, 
while infusion of a viral vector that blunts NPY signaling (rAAV-FIB-NPY13-36) 
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attenuated, ethanol-induced locomotor activity, respectively, relative to controls. 
Conversely, intra-striatum infusion of the rAAV-FIB-NPY vector, which increases 
NPY signaling, led to decreased ethanol-induced locomotor activity suggesting that 
NPY signaling in the NAc core and striatum modulate the locomotor stimulant effects 
of ethanol in a brain region-specific manner. 
The striatum and nucleus accumbens core are both regions known to be 
involved in motor behavior. These regions are topographically orgainized, distinct 
structures with similar histological and neurochemical characteristics wherein both 
regions contain primarily GABAergic medium spiny neurons which co-localize with 
various neuropeptides including NPY (Groenewegen, 2003; Smith & Bolam, 1990; 
Vuillet et al., 1990). However, efferent innervation and afferent projection areas, as 
well as receptor distribution in projection neurons, differ between these structures. 
Specifically, both the striatum and nucleus accumbens core project to regions of the 
substantia nigra pars comapacta, among others (Groenewegen, Wright, Beijer, & 
Voorn, 1999; Herrero et al., 2002; Voorn, Vanderschuren, Groenewegen, Robbins, & 
Pennartz, 2004). Importantly, the striato-pallidal neurons are known to express 
dopamine D2 receptors and are thought to be responsible for movement inhibition 
(Ade, Janssen, Ortinski, & Vicini, 2008; Gerfen et al., 1990), while accumbonigral 
projections contain both dopamine D1, thought to enhance movement, and D2 
receptors (Robertson & Jian, 1995). Therefore, neurobiological contributions arising 
from differential neurocircuitries and specific interactions with other neurotransmitter 
systems may contribute to the opposing effects on ethanol-induced locomotor 
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behaviors following chronic secreton of NPY observed in the striatum versus the 
core of the nucleus accumbens.  
Importantly, permanent changes within the dopaminergic brain circuits are 
known to result from psychomotor stimulant sensitization (Kalivas & Stewart, 1991). 
Whether these changes are a result of direct dopamine modifications or whether it 
results from interactions with other neurotransmitter systems is a matter of debate. 
Based on our results, an interesting possibility is that NPY may modulate ethanol-
induced locomotor behaviors via interactions with dopamine signaling within the 
striatum and core of the nucleus accumbens. Previous literature has proposed a 
relationship between the dopamine and NPY systems such that each system has 
reciprocal regulatory control over the other (Heilig & Widerlov, 1990; Josselyn & 
Beninger, 1993; Kerkerian, Salin, & Nieoullon, 1988; Midgley et al., 1994). To that 
end, early studies revealed that ICV administration of NPY enhanced endogenous 
dopamine release in striatal regions (Kerkerian-Le Goff et al., 1992). Further, in vitro 
data suggests that NPY administration is able to enhance dopamine release in the 
nucleus accumbens of rats (Ault, Radeff, & Werling, 1998). Consistently, dopamine 
has been shown to stimulate NPY gene expression while lesions of nigrostriatal 
dopaminergic neurons led to a decrease in NPY immunoreactivity in the NAc core 
(Lindefors, Brene, Herrera-Marschitz, & Persson, 1990; Salin, Kerkerian, & 
Nieoullon, 1990). Therefore, future research is required to examine the exact 
NPY/dopamine signaling interactions that may contribute to ethanol-induced 
locomotor activity and behavioral sensitization.  
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Taken together, we show that NPY signaling plays a role in the modulation of 
ethanol-induced locomotor behaviors likely via interactions with the dopamine 
system in the striatum and nucleus accumbens core. Therefore, future research 
should further investigate this hypothesis.     
 
The Role of Chronically Secreted Amygdalar NPY in Ethanol Consumption  
and Ethanol Dependence 
 
 The amygdala is known to be involved with both positive and negative 
emotional reactions and has been described broadly as the “centerpiece of the 
emotion system of the brain” (LeDoux, 1995). This region has been shown to be a 
critical brain structure in interpreting stimuli and integrating the appropriate 
behavioral, autonomic, and endocrine responses with a large body of evidence 
consistently implicating the amygdala in the aquistion and expression of conditioned 
fear (Davis, Rainnie, & Cassell, 1994; LeDoux, 1992; LeDoux, 2000). Further, 
amygdalar NPY signaling has been hypothesized to play a part in the modulation of  
these responses (Heilig, Koob, Ekman, & Britton, 1994; Heilig et al., 1993). 
Importantly, selectively bred alcohol-preferring (P) rats and High Alcohol Drinking 
(HAD) rats, as well as inbred high ethanol consuming C57BL/6J mice, exhibit 
decreased levels of NPY in the amygdala suggesting that amygdalar NPY signaling 
may also modulate ethanol consumption (Ehlers et al., 1998; Hayes, Knapp, Breese, 
& Thiele, 2005; Hwang et al., 1999). However, original studies indicated that acute 
NPY administered into the central nucleus of the amygdala failed to reduce the 
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consumption of a 10% ethanol solution in Wistar rats (Katner et al., 2002). 
Interestingly, ICV administration of NPY was unable to reduce ethanol consumption 
in Wistar rats or in alcohol non-preferring (NP) rats but was effective in attenuating 
the high ethanol consumption characteristic of the selectively bred P rats (Badia-
Elder et al., 2001).   
 The aforementioned results are consistent with the allostasis model of 
addiction which hypothesizes that as an individual cycles through repeated ethanol 
exposure, abstinence, and relapse, the positive reinforcing actions of ethanol 
become diminished as the negative affect associated with abstinence and 
withdrawal is magnified (Koob & Le Moal, 2001). Therefore, the original euphoria, 
disinhibition, and anxiety reduction associated with alcohol use are replaced with 
heightened dysphoria, depression, irritability, and anxiety thus promoting an 
increased vulnerability to relapse and leading to a perpetuation of the addiction 
cycle. It has been postulated that decreases in the activity of the NPY system 
combined with an increased activation of the corticotropin-releasing factor (CRF) 
brain stress system within regions of the extended amygdala may underlie the 
development of ethanol dependence arising from repeated cycles of ethanol 
exposure, abstinence, and relapse (Koob, 2003). Consistently, decreased levels of 
NPY were observed in the amygdala of Sprague-Dawley rats following forced 
exposure to a nutritionally complete liquid diet containing ethanol and an acute 
withdrawal period (Roy & Pandey, 2002). Therefore, increased NPY signaling may 
only modulate ethanol responses in animals with a chronic history of ethanol 
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consumption or dependence or in animals that entail alterations in this system 
stemming from genetic selection procedures.  
 Recent studies have supported this hypothetical model of addiction. 
Specifically, centrally infused NPY can reduce ethanol drinking in unselected Wistar 
rats exposed to 8 weeks of intermittent ethanol vapor while NPY administration was 
ineffective in non-vapor-exposed animals (Thorsell, Slawecki, & Ehlers, 2005). 
Further, when infused with CSF, Wistar rats made ethanol-dependent via forced 
consumption of an ethanol-containing diet displayed elevated operant alcohol-
reinforced lever pressing compared to non-dependent rats. On the other hand, 
dependence-induced increases in ethanol drinking were abolished following acute 
infusion of NPY directly into the central nucleus of the amygdala (Gilpin, Misra, & 
Koob, 2008). Consistently, in chapter 4, we showed that C57BL/6J mice infused with 
a virus which promotes increased synthesis and secretion of NPY into the amygdala 
displayed reduced ethanol consumption following approximately 2 months of ethanol 
access. Furthermore, following amygdalar infusion of a Sindbis viral vector which 
promoted the overexpression of NPY, Wistar rats exhibited blunted dependence-
induced increases in ethanol consumption (Thorsell et al., 2007). Further, in anxious 
rats, ethanol preference for a 6% ethanol solution was decreased following bilateral 
infusions of a viral vector encoding NPY into the central nucleus of the amygdala 
and was enhanced in response similar infusion of an NPY anti-sense virus 
(Primeaux, Wilson, Bray, York, & Wilson, 2006).   
  In our experimental manipulation, exposure to repeated ethanol vapor and 
withdrawal failed to elicit dependence-induced increases in ethanol drinking, even in 
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control mice. Therefore, we can not make any statements as to the role of 
amygdalar NPY signaling in ethanol dependence based on the results presented 
herein. However, had we observed increases in ethanol consumption following 
multiple cycles of ethanol vapor and withdrawal, we would have expected amygdalar 
rAAV-FIB-NPY transduction to attenuate dependence-induced increases of ethanol 
intake. In fact, since the rAAV-FIB-NPY vector provided constitutive secretion of 
NPY over the entire course of vapor exposure and withdrawal cycles, the effects 
may have been even more robust than previous studies which only examined the 
role of NPY in the expression of ethanol dependence.  
  Interestingly, mice exposed to ethanol vapor did exhibit enhanced withdrawal-
induced anxiety-like behavior compared to air-exposed mice consistent with 
previous literature (Kotlinska & Bochenski, 2008; Overstreet, Knapp, & Breese, 
2002; Santucci, Cortes, Bettica, & Cortes, 2008; Valdez et al., 2002; Zhang, Morse, 
Koob, & Schulteis, 2007; Zhao, Weiss, & Zorrilla, 2007). Importantly, recent studies 
have shown that mice with a partial deletion of the CREB gene express lower levels 
of NPY and display more anxiety-like behaviors than wildtype controls (Pandey et 
al., 2004). Further, infusion of NPY into the central nucleus of the amygdala of 
alcohol-preferring P rats was able to protect against elevated anxiety-like behavior 
characteristic of P rats (Pandey, Zhang, Roy, & Xu, 2005). Consistently, intra-
amygdalar administration of a Sindbis viral vector containing NPY cDNA promoting 
the overexpression of NPY reduced anxiety-like behavior in the open field test 
(Thorsell et al., 2007). However, results from our experiment unexpectedly failed to 
reveal an attenuation of the increased withdrawal-induced anxiety-like behavior 
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following viral vector-mediated chronic amygdalar NPY administration. This 
discrepancy may be due to procedural differences. In our study, rAAV-FIB-NPY was 
infused into ethanol naïve mice and was chronically secreted throughout the course 
of the multiple cycles of ethanol vapor exposure and withdrawal, while the virus in 
the Thorsell et. al. study (2007) was delivered following multiple exposures to 
ethanol vapor and withdrawals. Therefore, our manipulation may allow for possible 
neuroadaptations in receptor number and/or distribution within the amygdala which 
may have blunted the ability of the rAAV-FIB-NPY to produce robust effects on 
anxiety-like behavior. As is, our dependence paradigm seems to separate anxiety-
like behavior from ethanol consumption as increased anxiety-like behavior following 
ethanol vapor exposure did not correlate with subsequent increases of voluntary 
ethanol consumption.  
 To date, most research concerning the role of NPY in ethanol consumption 
has focused on NPY signaling in the amygdala. However, the allostasis hypothesis 
of drug addiction implicates blunted NPY signaling within the entire extended 
amygdala as a potential contributor to the neurobiological underpinnings of 
addiction. The extended amygdala includes not only the central nucleus of the 
amygdala but also the shell of the nucleus accumbens and the bed nucleus of the 
stria terminalis (BNST). Interestingly, two separate studies have now shown that the 
high ethanol consuming inbred C57BL/6J mice display decreased innate levels of 
NPY in the nucleus accumbens shell compared to low ethanol consuming DBA/2J 
mice (Hayes et al., 2005; Misra & Pandey, 2003). Further, infusion of a PKA inhibitor 
in the nucleus accumbens shell of Sprague-Dawley rats led to decreased NPY 
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protein levels in this region and an increased ethanol preference which could be 
attenuated by coadministration of NPY (Misra & Pandey, 2006). Although less 
research on ethanol consumption has focused on the BNST, it has been shown that 
this region contains a substantial population of NPY immunoreactive fibers and cell 
bodies and a recent study has shown that electrolytic lesions of the BNST lead to a 
decrease in baseline ethanol consumption (Allen, Roberts, Bloom, Crow, & Polak, 
1984; Dhaher et al., 2008). While these results are quite prelimary, they suggest the 
possibility that NPY signaling within the NAc shell and/or the BNST is involved in the 
modulation of ethanol consumption and ethanol-related bahaviors. Therefore, future 
research should more thoroughly investigate the role of NPY signaling in these 
regions on ethanol consumption and dependence. 
  
Conclusions: NPY Modulates Multiple Neurobiological Responses to Ethanol 
 
 Previous research has demonstrated a role for NPY in neurobiological 
responses to ethanol with a large portion of literature focusing on its role in ethanol 
consumption (Koob, 2003; Thiele & Badia-Elder, 2003; Thiele, Koh, & Pedrazzini, 
2002; Thiele, Marsh, Ste. Marie, Bernstein, & Palmiter, 1998; Thiele, Sparta, Hayes, 
& Fee, 2004). However, experimental manipulations of the NPY system mainly relied 
on acute, short-term alterations of NPY signaling (Badia-Elder et al., 2007; Katner et 
al., 2002; Pandey et al., 2003). Therefore, one of the goals of this dissertation was to 
extend these previous findings to examine the role of chronic amygdalar NPY 
administration on ethanol consumption and ethanol dependence. We showed that 
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rAAV-FIB-NPY infused into the amygdala of C57BL/6J mice was able to modestly 
decrease ethanol consumption following an extended history of ethanol consumption 
but we were unable to assess the effects of this vector on dependence-induced 
drinking since ethanol vapor exposure did not significantly increase ethanol drinking 
in our C57BL/6J mice. 
 A second goal of this dissertation was to examine the possibility that NPY 
may be involved in ethanol-induced locomotor behaviors. To that end, we showed in 
chapter 2 that RIIβ -/- mice, which are known to exhibit enhanced ethanol-induced 
locomotor activity (Fee et al., 2006), displayed increased NPY signaling in the 
hypothalamus, nucleus accumbens core, and striatum suggesting a direct 
correlational relationship between NPY and ethanol-induced locomotor activity. In 
chapter 3, we further explored this potential relationship by utilizing pharmacological 
and genetic manipulations. Interestingly, NPY -/- mice displayed reduced ethanol-
induced locomotor behaviors while NPY Y1 -/- mice displayed enhanced ethanol-
induced locomotor behaviors. Furthermore, infusion of rAAV-FIB-NPY into the core 
of the nucleus accumbens enhanced while infusion of rAAV-FIB-NPY13-36 in the 
same region attenuated ethanol-induced locomotor behaviorsin DBA/2J mice. This 
patten was opposite in the striatum as increasing the production and secretion of 
NPY via the rAAV-FIB-NPY reduced ethanol-induced behavioral sensitization in 
DBA/2J mice.  
 The present findings are important for several reasons. First, the results 
extend previous findings indicating that NPY is involved in modulating various facets 
of alcoholism. Secondly, we showed that in behavioral analyses of two separate 
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models of addiction, allostasis and incentive-salience sensitization, NPY was shown 
to be involved albeit through very different neurocircuitry. Such observations may 
help expand the use and effectiveness of pharmacological targets aimed a NPY 
signaling in the treatment of alcoholism. 
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Appendix I 
RT-PCR Validation of Vector Activity In Vivo 
 
As previously described (Foti et al., 2007; Haberman et al., 2003), the vector 
derived NPY could not be visualized in vivo by immunohistochemistry, likely due to 
the fact that the secreted protein would be rapidly degraded, especially during the 
perfusion procedure. Thus, in vivo activity of the rAAV-FIB-NPY or rAAV-FIB-NPY13-
36 vector was validated by demonstrating the presence of vector derived mRNA (see 
Foti et al., 2007). To that end, mice from each viral vector experiment received an 
overdose of ketamine/xylazine cocktail (117 mg/kg and 7.92 mg/kg, respectively) 
and were subsequently decapitated. The brains were removed and the nucleus 
accumbens, striatum, or amygdala was dissected out. Tissue samples were then 
stored in RNAlater (Ambion, Austin, TX) at –20°C. Subsequently, the RNA was 
extracted from the tissue (Promega SV-40 total RNA isolation kit, Madison, WI) and 
reverse transcribed using AMV reverse transcriptase and oligo-dT primers.  The 
subsequent PCR reaction used primers designed to span the FIB-NPY or FIB-
NPY13-36 sequence which can only be derived from the AAV vector. The PCR 
product was separated on a 1.8% NuSeive agarose gel. 
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Figure A.1 RT-PCR for AAV-FIB-NPY mRNA after infusion into either the amygdala 
of C57BL/6J mice (lane A; 2 weeks post-infusion) or the nucleus accumbens core of 
DBA/2J mice (lane B; 3.5 months post-infusion). The appropriate PCR product of 
169 bp was found in both structures indicating the presence of virally derived mRNA 
in vivo.  
 
 
Figure A.2 RT-PCR for AAV-FIB-NPY mRNA 3.5 months post-infusion (lane A) or 
sham infusion (lane B) into the amygdala of C57BL/6J mice. The appropriate PCR 
product of 169 bp was found indicating the presence of virally derived mRNA in vivo 
at least 3.5 months after infusion. 
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Figure A.3 RT-PCR for AAV-FIB-NPY mRNA after infusion into the striatum of 
DBA/2J mice following behavioral experimentation (approximately 6 months post-
infusion). Mice 2 and 5 received the viral vector while mice 3 and 32 received 
control. B indicates a blank control lane. The appropriate PCR product of 169 bp 
was found indicating the presence of virally derived mRNA in vivo following rAAV-
FIB-NPY infusion in the striatum. 
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Figure A.4 RT-PCR for AAV-FIB-NPY13-36 mRNA after infusion into the nucleus 
accumbens of DBA/2J mice. Lane A shows the appropriate PCR product of 143 
base pairs. Lane B is a control reaction where the reverse transcriptase was omitted 
to ensure that amplification products originated from RNA and not DNA. Lane C is a 
blank control. 
 
  A B C 
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